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ABSTRACT 
PDCD4 is a downstream substrate of mammalian/mechanistic target of rapamycin 
complex 1/ S6 ribosomal protein kinase 1 (mTORC1/ S6K1) pathway. It is known as an 
apoptotic protein, a tumour suppressor and an mRNA translation inhibitor. 
  PDCD4 expression at the onset of differentiation was significantly greater than on 
Day 0, the time of change from growth to differentiation medium (p<0.05). This 
observation is corresponding to the mRNA expression (p<0.05). Using the pulse-chase 
technique, PDCD4 degradation rate was significantly different between Day 0 and Day 1 
(p<0.05). Taking together, these imply that PDCD4 abundance during the onset of 
differentiation is likely regulated at the level of both protein synthesis and degradation. 
siRNA-mediated knockdown of PDCD4 led to a decrease in myogenic protein 
abundance during differentiation (p<0.05), and overexpression of PDCD4 stimulated 
differentiation (p<0.05).  
My study showed that the regulation of PDCD4 level may help in the 
management of muscle atrophy. 
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INTRODUCTION                                           
 
Maintaining skeletal muscle mass is a crucial factor in human health for people of 
all ages. The maintenance of muscle mass is essential for mobility, disease prevention 
and quality of life (1).  By vaguely saying “making muscles”, we can talk about two 
different processes. One is making existing muscles bigger, and the other is making new 
muscles.  “Making existing muscles bigger” for adults is done through physical activity, 
particularly resistance training. “Making new muscles” occurs after injury for adults. The 
healing process in the elderly population is not optimal since satellite cells decrease with 
aging (2, 3).  
In recent studies, apoptotic cells have provided new insight into the formation of 
new muscle. Apoptotic cells can induce myotube formation (4). PDCD4, a more recently 
discovered downstream substrate of mammalian/mechanistic target of rapamycin 
complex 1/ S6 ribosomal protein kinase 1 (mTORC1/ S6K1) pathway, is known as an 
apoptotic protein. It is also known as a tumour suppressor and an mRNA translation 
inhibitor (5). My thesis focuses on the role of PDCD4 in muscle cell (myotube) 
formation. 
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LITERATURE	  REVIEW	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   
2.1 Factors affecting muscle mass 
Muscle mass comprises approximately 40% of the average adult body weight (6, 
7). The functions of skeletal muscle tissue include body movement and maintenance of 
posture (8).  It is also a tissue that plays an important role in metabolizing glucose, fatty 
acids and amino acids. If we cannot maintain muscle mass, it is detrimental to our quality 
of life. In general, the mammalian body maintains a balance of protein synthesis and 
degradation. If there is a positive net anabolism, muscle hypertrophy (growth) can occur. 
On the other hand, if the net protein balance is negative, muscle wasting (atrophy) can 
occur (9). Two of the factors that influence net protein balance are physical exercise and 
nutritional conditions (10).  Muscle mass and integrity are affected by age. 
 
2.1.1 Exercise  
Exercise/physical activities can maintain overall health and wellness. The reason 
for doing exercise is varied, and the type of exercise also varied. However the health 
benefits are the same: improve physical health such as a better immune system which 
leads to disease prevention, and mental health such as improving self-esteem and 
preventing depression. On the other hand, inactivity such as bed-rest and space flight- 
induced muscle atrophy is associated with decline in peak power and force (11-14). If 
humans experience 130 days of bed rest, we experience 90% of peak torque force loss 
(15).  
 The American College of Sports Medicine (ACSM) recommends that most adults 
carry out moderate-intensity cardiorespiratory exercise training for at least 30 minutes for 
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5 days a week, or vigorous intensity cardiorespiratory exercise training for at least 20 
minutes 3 days a week. They also mention the importance of maintaining joint range of 
movement, flexibility, balance, coordination and agility as well (16).  
Exercise is a stimulus that promotes protein synthesis and insulin sensitivity. 
Resistance training is beneficial for muscle mass and strength. Endurance training 
improves numerous metabolic functions, such as insulin-induced glucose metabolism and 
mitochondrial function (17). Compared to resistance training, aerobic exercise is less 
stressful on muscles. Therefore, endurance training leads to minor muscle adaptation 
compare to resistance training (7). However both low- and high-intensity exercise 
contribute to maintaining body weight and protein synthesis (18).  
The resting metabolic rate (RMR) is the largest component and approximately 60-
70% of daily energy expenditure (19). Fat-free mass (FFM) is an important component 
for RMR. FFM consists of high metabolic rate organs and tissues such as skeletal muscle, 
brain, heart, liver and kidney, and low metabolic rate tissues such as bone (20, 21). The 
lean tissue loss, which is usually associated with dieting, leads to lower RMR. Because of 
this, dieters may not achieve long-term weight maintenance. It is also widely accepted 
that RMR progressively decreases with age (22). Therefore, exercise, particularly 
strength training has the greatest effect for preventing aging and obesity. Macronutrient 
particularly protein has an important role to increase or maintain FFM and building 
muscle. However, all nutrient are likely important for optimal muscle mass.  
 
2.1.2. Nutrition 
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Human beings, like all animals, are heterotrophs. Unlike autotrophs, such as 
plants, we cannot produce organic compounds from inorganic compounds. Therefore we 
have to rely on ingesting other organisms to obtain organic compounds to sustain our 
lives and maintain our health. Those organic compounds are mainly carbohydrate, fat and 
protein. The acceptable macronutrient distribution ranges (AMDR) are 45-65% for 
carbohydrate, 20-35% for fat and 10-35% for protein. However, people tend to ingest 
food more than they need, which accumulates in one’s body and leads to obesity. 
 
2.1.2.1 Nutritional effect on obesity  
During evolution, our ancestors faced famine regularly. Therefore, individuals 
who could have an efficient fat deposition during food abundant time period had a higher 
chance to survive. This genetic evolution, thrifty genes, is not suitable in recent decades 
(23). Due to the technological improvement, we do not need to store food in our body (24, 
25). Instead of having famine, we are facing to the prevalence of obesity. People move 
less and eat more, which is completely opposed to our ancestor’s lifestyle. 
Obesity is known as multi risk factor for many diseases including diabetes, 
cardiovascular disease and cancer. Obesity occurs through the imbalance between energy 
intake and energy expenditure. The excess energy accumulates as fat in our body. If the 
imbalance between energy intake and output causes problems, eat less and do exercise. In 
reality, it is not easy to achieve in a long-term maintenance of weight loss (25). Caloric 
restriction has many beneficial effects including insulin sensitivity and obesity in many 
species including human being (26, 27). Caloric restriction does not mean starvation. It is 
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the absence of malnutrition in nutrient intake reduction. However, the precise caloric 
intake is unknown for human.  
 
2.1.2.2 Protein ingestion and protein synthesis 
It is known that people tend to take in more protein than they need in a day 
(>0.8g/kg). On the other hand, older generations are not ingesting enough protein due to a 
reduced appetite (28). In addition to lower ingestion, studies show that elderly and obese 
populations have a lower protein synthesis rate even when ingesting the same amount of 
protein as others due to the insulin insensitivity (29-32). This leads to the idea that having 
excess amount of protein may help their condition. The problem is that excess amounts of 
protein do not build muscle. Research showed that protein supplementation solely does 
not help muscle wasting condition. Physical activity is the most important factor in 
improving muscle atrophy (33-35).  
 
2.1.2.3 Carbohydrate/protein ingestion for protein synthesis 
Low carbohydrate diet improves insulin resistance due to reduction of blood 
glucose (36-39). The criticism of this diet relates to the increase of saturated fat ingestion 
as a substitute for the carbohydrate (40). Nowadays, low fat diet is accepted as healthy 
diet, therefore low carbohydrate diet is more likely associated to high protein diet. The 
increase rate of some diseases such as kidney disease is related with a high protein diet 
(41, 42). This observation is controversial. For pre or existing kidney disease individuals, 
protein restriction may improve the condition. However if subjects are healthy people, 
studies did not observe the correlation between high protein diet and kidney disease (43, 
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44). Even so, obesity and aging are multi-risk factor, therefore being cautious is 
important. For example, elderly patients with type 2 diabetes who did physical activity 
with inadequate protein intake observed negative effects to their health (45). Since the 
debate is still inconclusive, following the RDA of 0.8g/kg/day and 10-25% of daily 
energy consumption is the safe choice (28, 45).  
If people can keep the quantity of protein, the quality and timing of protein 
ingestion may change the absorbance. 
 
2.1.2.4 Nutritional ingestion post exercise for protein synthesis 
Protein ingestion, particularly the amino acid, leucine is known to induce protein 
synthesis (46, 47). People who want to build muscle tend to eat meat products in addition 
to taking protein supplements such as whey protein, branched chain amino acid (BCAA) 
powder and so on. However, ingestion of carbohydrate too after resistance training 
improves the net protein balance. It was primarily due to the decrease of protein 
degradation. Carbohydrate ingestion alone is not as effective as protein ingestion alone 
(48). However, not only amino acids, but also insulin plays a key role (46). Leucine 
stimulation of protein synthesis is most effective in the presence of insulin (49, 50).  
During exercise, fuel selection is determined by exercise intensity and duration. 
High intensity exercise of short duration relies on muscle glycogen for adenosine 
triphosphate (ATP) provision, and carbohydrate is a major fuel (51, 52). In body builders, 
thirty minutes of resistance exercise caused muscle glycogen concentration to be reduced 
by 26% lower after the exercise (53). Ingestion of carbohydrate during resistance exercise 
also the increased the amount workload before exhaustion (54). Therefore, carbohydrate 
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ingestion during and post resistance training enhances muscle glycogen synthesis and a 
quick recovery (54, 55). Ultimately carbohydrate ingestion is important for building 
muscle. 
Protein ingestion post exercise is important for athletes to maximize the muscle 
adaptive response, such as muscle hypertrophy (17). The resistance training effect on 
protein synthesis works for up to 24-48 hours after exercise (9, 56-58). However, not 
only protein synthesis, but also protein degradation too is increased by resistance training 
(9). Without nutrient intake, net protein balance is negative (59). Therefore the timing of 
nutrient ingestion is another important factors that can affect protein synthesis. The 
generally accepted idea is that amino acids/protein ingestion should be right after the 
exercise in order to activate mTORC1 and increase the rate of protein synthesis (56). 
Ingesting protein for elderly, the timing is crucial. The muscle mass gain is significantly 
lowered for people who ingested protein 2 hour post exercise compared to immediately 
after resistance exercise (60). The ingestion of whole milk post resistance training 
demonstrated more positive net protein balance compared to fat free milk (61). Even so,  
low fat or fat free milk ingestion after exercise is also beneficial for not only net protein 
balance, but also strength and muscle hypertrophy as well (62-64). Moreover, low fat/fat 
free milk ingestion gives higher net protein balance than ingesting soy milk (62, 64). This 
is due to the lower bioavailability of soy milk compared to animal milk (47). Instead of 
taking fancy protein supplementation, elderly can increase protein synthesis with one of 
their regular food items (i.e. milk). This should be consumed immediately after their 
exercise. It is important for elderly population to aware of the high probability of age- 
related muscle wasting condition, such as sarcopenia. The factors causing those 
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conditions are not only genetic, but also environmental, meaning they are preventable 
(65-68). Although aging cannot be prevented, delaying aging can be achieved through 
adequate intake of nutrition such as caloric restriction and protein intake and exercise (26, 
27, 69).  
 
2.1.3 Aging and sarcopenia 
Eternal youth and immortality is a dream. Historical heroes and heroines tried 
many things for their longevity. In the beginning of the eighteen-century, half of the 
population died before 10 years of age. Improvements in hygiene and environment, 
reduction of the rate of infant mortality and improvements in medicine made the average 
life span longer. On the other hand, the worldwide prevalence of elderly population 
challenges health care system in this century. Aging is associated with changes in body 
composition, leading to a loss of lean tissue and a corresponding increase in body fat 
(18). Sarcopenia is characterized by a deterioration of muscle quality and quantity due to 
the age-related reduced amount of anabolic stimuli (7, 28, 70). Sarcopenia affects 
approximately 15% of those over 65 years old, and 50% of those over 85 years old (71). 
Among young adults, 40-50% of body weight is lean muscle mass. However in those 75-
80 years old, only 25% of body mass is lean muscle mass. Sarcopenia is most notable in 
the lower limb muscle loss, and type II muscle atrophy is observed (72, 73). Because 
sarcopenia is a gradual muscle wasting condition, it is the least understood of muscle 
wasting conditions (71). 
Aging is the process of degenerating or destroying of homeostatic functions of 
individuals. The DNA damage is cumulative, even though the DNA damage is supposed 
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to repair during meiosis. As a result, cell replication and transcription are interfered, it 
causes loss of cell function and apoptosis (74), malfunctioning can lead to cancer cell 
proliferation as well. The repairing function of DNA and longevity are correlated. 
Both caloric restriction and nutrient sensing pathway are well known to decrease 
the incidence of diseases and age related lowering body function such as loss of insulin 
sensitivity, bone, immune and motor dysfunction (75).  
 
2.1.3.1 Insulin/ IGF-1 and mTORC1 pathway and aging 
Reduced insulin/ insulin-like growth factor I (IGF-I) signalling pathway increases 
lifespan and health span. Reduction of insulin/IGF-1 activities is through caloric 
restriction or growth hormone deficiency; those conditions showed lifespan increase in 
rodents (67, 75). Overexpression of IGF-I or its receptor has been found in malignancies 
in children and adults. On the other hand, congenital IGF-I deficient individuals did not 
have any cancers, even though family members experienced malignancy in human (76). 
Heterozygous IGF-I receptor (IGF-IR) knockout mice also showed longer life span 
compared to their littermates. Those mice did not have any difference in energy 
metabolism, nutrient uptake, fertility, reproduction or physical activity compared to their 
littermates. Moreover, IGF-IR mutant mice showed greater resistance to oxidative stress, 
which is aging determinant (77). Having IGF-I deficiency causes developmental defects. 
Their body size is smaller compared to their littermates. This is because insulin/IGF-I 
signaling is linked to the activities of mTORC1/S6K1signaling, a pathway important for 
regulate muscle mass (Fig 2). 
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 mTORC1/S6K1 pathway is activated by amino acids independently. 
mTORC1/S6K1 pathway inhibition increases longevities of species. The difference 
between rodents and humans is that caloric restriction is effective on decrease of IGF-1 in 
rodents, however human IGF-1 reduction can be observed with reduced intake of protein. 
Even so, the change in study method was 1.67g/kg of body weight per day to 0.95 g/kg of 
body weight per day for 3 weeks (67). It shows that we should follow the RDA’s 
recommendation (0.8g/kg) (28, 45).  
  
  
2.2 mTORC1 and regulation of muscle mass  
2.2.1 mTORC1  
mTORC1 is known as a master regulator of cell growth, proliferation and 
metabolism. mTORC1 is regulated by growth factors, energy/oxygen status and nutrients. 
Therefore, having adequate amount of mTORC1 is important for cell growth and 
proliferation. This is because mTORC1 regulates the synthesis of nucleotides, lipids, 
proteins, mRNA and autophagy (78-80). On the other hand, improper regulation of the 
mTORC1 pathway leads to uncontrolled cell proliferation as can be seen in cancer (79, 
81). There is a drug, rapamycin, which is an mTORC1 inhibitor that is also used for some 
cancer treatments. It was discovered in Easter Island (Rapa Nui) from soil samples. It is 
an antifungal metabolite produced by streptomyces hygroscopicus (mycin is a suffix for 
antibiotics produced by Streptomyces strains). It has been on the market in the U.S. since 
September 1999.  It has immunosuppressant functions and is administered to prevent 
rejection in kidney transplants (82-86). It has also received attention in the public since 
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mice administered this drug showed prolonged life span (87). mTORC1 researchers often 
use rapamycin to inhibit the function of the complex (88). Rapamycin binds 12 kDa 
FK506-binding protein (FKBP12), and the rapamycin and FKBP12 complex directly 
binds to mTORC1 and inhibits mTORC1 pathway (79, 89).  
 
2.2.2 The structure of mTORC1 
As the name suggested, TOR was discovered as a target of rapamycin in yeast. 
mTOR (also known as FRAP, RAFT or RAPT) was identified as the ortholog of the yeast 
TOR1/2 in 1994 (84, 90). mTOR is  identified as a member of two distinct complexes  
termed mTORC1 and mTORC2. mTORC1 consists of mTOR, proline-rich AKT 
substrate 40 kDa (PRAS40), DEP domain containing mTOR-interacting protein 
(DEPTOR), mammalian lethal with SEC13 protein 8 (mLST8) and regulatory-associated 
protein of mTOR (raptor). On the other hand, mTORC2 consists of mTOR, mLST8, 
DEPTOR, rapamycin insensitive companion of mTOR (rictor), mammalian stress-
activated protein kinase (SAPK) interacting protein 1 (mSIN1) and proline rich protein 
5/protein observed with rictor (PRR5/protor) (81, 91-94).  
  mTOR is a serine/threonine kinase with high molecular weight (289 kDa), and 
contains 2549 amino acids. From the N-terminal to C-terminal, mTOR contains I) 20 
Huntington, elongation factor 3 (EF3), a subunit of protein phosphatase 2 (PP2A), TOR1 
(HEAT) repeats domain, II) FKBP12-rapamycin-binding domain of FKBP-rapamycin-
associated protein (FRAP), Ataxia telangiectasia mutated (ATM), 
Transformation/transcription domain-associated protein (TRRAP) (FAT) domain, III) 
FKBP-rapamycin binding (FRB) domain, IV) the kinase domain, V) FAT-C-terminal 
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(FATC) domain. FRB domain binds the FKBP12- rapamycin complex (79, 95, 96) (Fig 
1). 
Raptor is an mTOR binding protein with a mass of 150 kDa. It also binds p70 S6 
kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and act as 
an mTOR scaffold protein. The interaction between raptor and S6K1 or 4E-BP1 is 
through TOR signalling (TOS) motif, which is in the N terminus of S6K1 and is in the C 
terminus of 4E-BP1 (97-100). When raptor is knocked down, there is a decrease in S6K1 
phosphorylation and cell size reduction (80). However overexpression of raptor increases 
the mTORC1 signalling (95). In nutrient abundant situation, raptor has a positive role 
particularly enhancing the mTORC1 activity toward S6K1 (80, 95). Under low energy 
state, the gamma subunit of 5’ adenosine monophosphate-activated protein kinase 
(AMPK) phosphorylates raptor at Ser 722 and Ser 792 and represses mTORC1 activity 
(101-103). 
mLST8 is a 36 kDa protein that binds to the kinase domain of mTOR. It is also 
identified as G protein β-subunit-like protein (GβL) (82). When mLST8 is knocked-down 
there is a decrease in mTORC1 signalling and cell size reduction, however 
overexpression of mLST8 increases mTORC1 signalling (81, 82). Both mTOR and raptor 
knockout mice die in early stage of embryo development, however mLST8 knockout live 
a little bit longer (104).  
Opposing the effects of raptor and mLST8, DEPTOR and PRAS40 negatively 
regulate mTORC1. DEPTOR interacts with the FAT domain of mTOR via a postsynaptic 
density 95, discs large, zonula occludens-1 (PDZ) domain located at its C terminus (105). 
Upon serum stimulation, DEPTOR is degraded by proteasome through ubiquitylation by 
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E3 ligase β-transducin repeat-containing protein (β-TrCP). Disturbing β-TrCP impairs 
DEPTOR degradation and it also impairs S6K1 phosphorylation. It leads to activation of 
autophagy and cell growth reduction occurs (101, 106). 
PRAS40 was first reported as a substrate of AKT. When insulin is depleted, 
PRAS40 disturbs mTORC1 activities. Therefore, PRA40 is regulated by insulin. PRAS40 
is a raptor binding protein (93, 94, 107). For binding raptor, TOS motif in PRAS40 is 
required (108, 109). PRAS40 binds the mTOR kinase domain under the conditions such 
as serum or nutrient deprivation or mitochondrial metabolic inhibition (110). After AKT 
phosphorylates PRAS40 on Thr 246, mTORC1 phosphorylates PRAS40 on Ser 183 and 
221, which then causes PRAS40 to dissociate from mTORC1 (111). 
 
 
 
Fig 1. The domain structure of mTOR and mTORC1 components 
mTORC1 components (mTOR, PRAS40, raptor, DEPTOR and mLST8) and mTORC1 
inhibitor, the complex of rapamycin and FKBP12 and their interaction site on mTOR. 
Raptor and mLST8 are positive regulators of mTORC1, and DEPTOR, PRAS40 and the 
complex of rapamycin and FKBP12 negatively regulate mTORC1.  Retrieved	  from	  Laplante	  M	  and	  Sabatini	  DM.	  Cell.	  2012;149(2):274-­‐93.	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2.2.3 Activation of mTORC1 
mTORC1 activation is predominantly regulated by nutrient availability. In 
addition to it, mTORC1 is activated by growth factor and stress signaling pathways. 
 
2.2.3.1 Activation of mTORC1 by growth factors 
Growth factors have capabilities of stimulating mammalian cell growth and 
proliferation through regulating cellular signalling pathways such as mTORC1. 
mTORC1 is activated by growth factors, such as insulin and insulin-like growth 
factor 1  (IGF-1), through the receptor tyrosine kinase (RKT)-AKT/PKB signalling 
pathway. Once the growth factor binds to receptor tyrosine kinases (RTK), the receptor is 
activated by autophosphorylation (112, 113). Activated RTK leads to recruitment and 
phosphorylation of insulin receptor substrate 1 (IRS-1), which also recruits 
phosphoinositide 3-kinase (PI3K). PI3K then converts phosphatidylinositol 4,5-
bisphosphate (PI(4,5)P2) to phosphatidylinositol (3,4,5)-triphosphate (PI(3,4,5)P3). PIP3 
then binds to the pleckstrin homology (PH) domain of AKT, which enables 
phosphoinositide dependent kinase 1 (PDK1) to phosphorylate and activate AKT (81, 91, 
94, 114). Prior to AKT phosphorylation by PDK1, Akt needs to be phosphorylated at Ser 
473 and Ser 450 by mTORC2. Following phosphorylation at the 2-serine residues, PDK 
phosphorylates Thr 308, which leads to Akt activation (115). Activated AKT indirectly 
stimulates mTORC1 by phosphorylating 2 proteins: PRAS40 and tuberous sclerosis 
protein 1 (TSC1)/ tuberous sclerosis protein 2 (TSC2) (10, 94, 116). 
TSC1/TSC2 exist as a heterodimer, and mutations in either of two genes cause 
tuberous sclerosis, a genetic disease in wide range of tissues, including brain. The tumor 
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growth in the brain causes serious medical complications: mental retardation, epilepsy 
and autism (117). TSC2 contains a guanosine triphosphatase (GTPase)-activator domain 
at its C-terminal end (91, 117).  It promotes hydrolysis of GTP bound to a G protein, Ras 
homolog enriched in brain (Rheb). If TSC2 is inactivated/phosphorylated by AKT on 
multiple sites, Rheb is in a GTP bound state and directly binds to mTOCR1 (91, 118, 
119). This activates mTORC1. 
 
2.2.3.2 Activation of mTORC1 by amino acids 
Amino acids are essential nutrients for all cells. Among amino acids, particularly 
leucine is known as one of the most important activator of mTORC1 (118, 120). Insulin 
stimulation without amino acids fails to activate 4E-BP1 and S6K1 (121). On the other 
hand, amino acid activation suffers when insulin is not present. Activation of mTORC1 
through amino acids has been speculated to be via inhibition of TSC1-TSC2, leading to 
the activation of Rheb (81). However, a study showed TSC2 is not necessary for amino 
acid activation of mTORC1 (122). For its activation, mTORC1 has to translocate to the 
surface of lysosome. mTORC1 activation by amino acids can occur through Rag 
guanosine triphosphatases (GTPases) and the Ragulator. Ragulator is a trimeric protein 
complex encoded by MAPKSP1, ROBLD3 and c11orf59 genes. Those proteins have 
been called MAPK scaffold protein 1 (MP1), p14 and p18 respectively (123, 124). There 
are 4 Rag proteins in mammals, RagA, RagB, RagC and RagD. Those form Rag 
heterodimers in which RagA or RagB binds with RagC or RagD. Rag heterodimers 
containing GTP-bound RagB interacts with mTORC1 (124, 125). Rag GTPases bind to 
the Ragulator on the surface of lysosome. Subsequently, the rag complex binds raptors, 
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but not mTOR (125) and mTORC1 is translocated to the lysosome, where Rheb-GTP is 
located. It leads to the activation of mTORC1 by Rheb (124, 125).  
In addition to the effects of the Rag proteins, amino acid stimulation of mTORC1 
signalling pathway is also sensitive to wortmannin, a PI3K inhibitor. A well known 
wortmannin target is class I PI3K, however it does not have any effect on amino acid 
induced mTORC1 activation. Instead, a class III PI3K protein, human vacuolor protein 
sorting 34 (hVps34) can mediate the activation of mTORC1 by amino acid (50). The 
hVps34/ human vacuolor protein sorting 15 (hVps15) heterodimer regulates endosomal 
sorting and trafficking and initiation of autophagy. Amino acids trigger elevation in 
intracellular Ca2+ concentration. This leads to elevation of binding of Ca2+/calmodulin 
(CaM) to hVps34 (126). This leads to increased mTORC1 activity. The depletion of 
hVps34 or hVps15 decreased S6K1 phosphorylation, and overexpression of hVps34 and 
hVps15 increased S6K1 phosphorylation.  
A Sterile 20 family protein kinase, mitogen-activated protein kinase 4-kinase 3 
(MAP4K3) was identified as another possible activator that induces mTORC1 pathway in 
response to amino acid. Depletion of MAP4K3 reduced S6K1 and 4E-BP1 
phosphorylation, on the other hand overexpression of MAP4K3 increased S6K1 
phosphorylation in a rapamycin sensitive manner. MAP4K3 also regulates cell growth 
(127, 128). 
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Fig 2.  mTORC1 signalling pathway: mTORC1 signalling pathway is activated by 
insulin/IGF-1 or amino acids. Activated insulin receptor tyrosine kinase (RTK) by 
insulin/IGF-1 binding phosphorylates IRS1. Ph-IRS-1 recruits PI3K, which converts PIP2 
to PIP3. Then, PIP3 translocates AKT to the membrane. AKT is phosphorylated/activated 
by PDK1.  AKT then phosphorylates TSC2.  This phosphorylation of TSC2 inhibits the 
TSC1/2 complex function as an inhibitor of Rheb function towards activation of 
mTORC1. A GTP-bound state of  Rheb activates mTORC1. mTORC1 phophorylates 
well known downstream substrates, S6K1/2 and 4E-BP1. Once 4E-BP1 is 
phosphorylated by mTORC1, it dissociates from eIF4E, which is a component  of eIF4F 
complex. Amino acids activation is through the activation of Rheb.  
Retrieved from Fingar	  DC,	  Blenis	  J.	  Oncogene.	  2004;23(18):3151-­‐71. 
 
2.2.3.3 mTORC1 regulation by AMPK 
Even if cells have an adequate amount of amino acid, protein synthesis, a high energy 
consuming process, cannot occur under cellular energy stress, such as hypoxia, low 
energy state and exercise (102, 129). AMPK detects and is activated by the increase in 
the AMP: ATP ratio. AMPK regulates fatty acid oxidation and glucose uptake in skeletal 
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muscle (129). To conserve existing ATP levels, AMPK phosphorylates many 
downstream substrates including raptor (131). An analog of AMP, 5-aminoimidazole-4-
carbozamideribonucleoside (AICAR), is considered a useful tool to activate AMPK in 
research. Unlike other activators of AMPK, such as 2-deoxyglucose, or high fructose, or 
heat shock and inhibitors of oxidative phosphorylation, AICAR is able to activate AMPK 
without disturbing ATP, adenosine diphosphate (ADP) and AMP concentrations (130). 
AMPK directly phosphorylates TSC2 on Ser1345 and Thr1227, which increases TSC2 
GAP activity toward Rheb. This suppresses Rheb/mTORC1 activation.  AMPK also 
phosphorylates raptor and inhibits mTORC1 directly (131). 
 
2.2.4 Downstream target of mTORC1 and mRNA translation  
The substrates of mTORC1 activities are involved in mRNA translational control, 
ultimately protein synthesis. In this regard, the two well-studied downstream substrates of 
mTORC1 are S6K1 and 4E-BP1 (79, 81, 131). The phosphorylation of 4E-BP1 by 
mTORC1 frees eukarytic translation initiation factor 4E (eIF4E) which can then form the 
eukarytic translation initiation factor 4F (eIF4F) complex (the complex of eukarytic 
translation initiation factor 4A (eIF4A), eukarytic translation initiation factor 4G (eIF4G) 
and eIF4E) (131).   
S6K1 and S6K2 are two S6K isoforms in mammalian cells and they are 80% 
identical (132). Both of them are direct targets of mTORC1 and are phosphorylated and 
activated by mTORC1. S6K1 is more studied, and characterized due to the fact that it 
was discovered earlier than S6K2. S6K1 is phosphorylated by mTORC1 on Thr 389. It is 
subsequently phosphorylated on Thr 229 in the T-loop region by PDK1 (133, 134). 
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Activated S6K1 phosphorylates numerous downstream targets, such as the ribosomal 
protein S6 (rpS6), eIF4B and PDCD4, all of which appear to play important roles in 
mRNA translation and ribosome biogenesis. rpS6 is the most characterized substrate of 
S6K1. This component of the 40S eukaryotic small ribosomal subunit protein (40S) has 5 
phosphorylation sites: Ser 235, Ser 236, Ser 240, Ser 244 and Ser 247. Phosphorylation 
of S6 has a role in the translation of mRNA having a 5’ terminal oligopyrimidine tract (5’ 
TOP). However, the translational role of S6 is questioned (135, 136).  
Phosphorylation of eIF4B on Ser 422 activates eIF3 directly. eIF3 binds to eIF4G 
which bridges the mRNA with 40S ribosome (137).  
A more recently discovered substrate of S6K1 is PDCD4. It is phosphorylated on 
Ser 67 and then subsequently ubiquitylated by E3 ligase β-TrCP and degraded by the 26S 
proteasome. PDCD4 is also phosphorylated on Ser 71 and Ser 76 allowing for binding to 
β-TrCP. If PDCD4 is not phosphorylated, it binds to eIF4A which prevents formation of 
eIF4F (Fig3). To start translation, the 40S ribosome subunit and eIF2-GTP-Met-tRNA 
form 43S pre-initiation complex (PIC) (138).  This complex binds to mRNA via the 
eIF4F complex (the complex of eIF4A, eIF4G and eIF4E). This complex is called the 
48S PIC. Once 48S PIC finds a starting codon on mRNA, 60S ribosome bind to 40S 
ribosome and form 80S ribosome and leads to translation (79, 81, 139).    
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Fig 3. General overview of mTORC1 signaling and PDCD4 regulation 
Once mTORC1 is activated, its downstream substrate S6K1 is phosphorylated. S6K1 can 
phosphorylate PDCD4. If PDCD4 is not phosphorylated, it attaches to eIF4A, a part of 
eIF4F complex. As a result, it inhibits mRNA translation. Phosphorylated PDCD4  
(Ser67) is targeted for ubiquitin-mediated degradation by the ubiquitin protein ligase 
βTrCP (beta transducing repeat containing protein). 
 
 
2.2.4.1 eIF4G 
eIF4G is an adaptor protein and a mediator of mRNA binding to the 43S PIC. 
eIF4G coordinates to scaffold eIF4E, eIF4A, eIF3, 3’–end bound poly (A)-binding 
protein (PABP) and RNA. eIF4G contains 3 domains; N-terminal one-third of eIF4G 
(4G-N), middle one-third of eIF4G (4G-m) and C-terminal one third of eIF4G (4G-C). 
4G-N is amino acids (AA) 1 to 634, 4G-m is AA 635 to 1039, and 4G-C is AA 1040 to 
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1560. PABP binds to the 4G-N AA 132 to 160, eIF4E binds to the 4G-N AA 570 to 582, 
eIF3 binds to the 4G-m AA 672 to 1065 and eIF4A has two binding sites within 4G-m 
AA 672 to 970 and 4G-C AA 1201 to 1411 (140-142) (Fig 4).  
 
 
 
Fig 4. Structure of eIF4G domain 
eIF4G contains 3 domains in N-terminal (AA 1 to 634), middle-terminal (AA 635 to 
1039) and C-terminal (1040 to 1560).  Binding sites of proteins (PABP, eIF4E, eIF3 and 
eIF4A) are depicted. Retrieved	  from	  Morino	  S,	  Imataka	  H,	  Svitkin	  YV,	  Pestova	  TV,	  Sonenberg	  N.	  Molecular	  	  and	  cellular	  biology.	  2000;20(2):468-­‐77.	  
 
 
2.2.4.2 eIF4E 
eIF4E is the 5’-methy-7-guanosine (m7GppN) cap-binding protein responsible for 
binding of the eIF4F complex to the mRNA cap structure (139, 143). The abundance of 
eIF4E is due to mTORC1 activation via the phosphorylation of a downstream target, 4E-
BP1. 4E-BP1, which acts as small molecular mimics to eIF4G, binds to eIF4E (139). 
When phosphorylated by mTORC1, it dissociates from eIF4E. This allows eIF4E to bind 
the C-terminal region is that the middle region of eIF4GI is
sterically hidden from free eIF4A by the C-terminal region.
eIF4A binds first to the C-terminal region and is subsequently
transferred to the middle region. This idea is consistent with
another feature of eIF4AIII: while eIF4AIII strongly binds to
the middle third of eIF4GI, it binds the full-length eIF4GI very
poorly (17). To distinguish between these models, dissociation
constants between eIF4A and each region or full-length of
eIF4GI ought to be determined. Also, the number of eIF4A
molecules that bind to eIF4GI at a given time will need to be
established.
The C-terminal third of eIF4G also plays a role in the phos-
phorylation of eIF4E. The distal C-terminal region of eIF4GI
contains a binding site for the serine/threonine kinase Mnk1
(Fig. 7). It has been shown that the C-terminal third of eIF4G
recruits Mnk1 to phosphorylate eIF4E in vivo (26, 30), which
is thought to stimulate cap-dependent translation. Phosphory-
lation of eIF4G itself may also affect translation. Interestingly,
several serum-responsive phosphorylation sites are localized in
the C-terminal third region of eIF4GI (B. Raught, A.-C. Gin-
gras, S. P. Gygi, H. Imataka, S. Morino, A. Gradi, R. Aeber-
sold, and N. Sonenberg, unpublished data).
What is the function of the N-terminal third of eIF4G? This
region harbors the eIF4E and PABP binding sites and conse-
quently engages the mRNA via both its 5! and 3! ends. While
the critical role of the eIF4E-binding site for cap-dependent
translation is confirmed in this study, our experiments did not
address the importance of the PABP binding site in transla-
tion, because the recombinant eIF4GI which we used lacked
this site. It should be very interesting, however, to examine how
translation is affected when mRNA is circularized through the
N terminus of eIF4G in a reconstituted translation system,
using full-length eIF4G. However, current models state that
the PABP interaction with eIF4G is not required for the first
round of translation initiation, but only for subsequent rounds
(28). The spacer region between the PABP and eIF4E binding
sites ("400 aa) is the least conserved region between eIF4GI
and eIF4GII (7). We do not know the function of this region;
no protein has been reported to bind this region, and its de-
letion had no effect on ribosomal binding (Fig. 2B) or on
translation in the reticulocyte lysate (Fig. 2C).
Finally, using the in vitro ribosome binding assay, we dem-
onstrated 48S ribosomal complex formation at the correct ini-
tiator AUG for the #-globin mRNA in the absence of eIF4E
(Fig. 1) or with an eIF4GI mutant lacking the eIF4E binding
site (Fig. 2B), albeit with low efficiency (20 to 24% of that of
the complete system). The eIF4E-independent ribosome bind-
ing does not seem to represent aberrant ribosomes binding,
FIG. 7. Demarcation of the Mnk1 binding site in the C-terminal region of
eIF4GI. (A) N-terminal boundary. GST, GST-CAT, or GST-eIF4GI deletion
mutants were coexpressed with FLAG-Mnk1 in HeLa cells. One-fortieth of the
cell extract was subjected to SDS-PAGE for Western blotting with anti-FLAG
antibody to confirm the expression of FLAG-Mnk1 (upper panel). The remain-
ing extract was mixed with glutathione-Sepharose beads. Bound proteins eluted
with reduced glutathione were subjected to Western blotting with an anti-GST
(middle panel) or anti-FLAG (lower panel) antibody. (B) C-terminal boundary.
GST, GST-CAT, or GST-eIF4GI deletion mutants were coexpressed with
FLAG-Mnk1 in HeLa cells. One-fortieth of the cell extract was subjected to
SDS-PAGE for Western blotting with anti-GST antibody to confirm the expres-
sion of GST fusion proteins (upper panel). The remaining extract was immuno-
precipitated with anti-FLAG antibody, and immunoprecipitates were subjected
to Western blotting with anti-FLAG (middle panel) or anti-GST (lower panel)
antibody. IgG, immunoglobulin G.
FIG. 8. Model of eIF4GI functional domains. Previous studies have mapped
the eIF4E (18) and PABP (13) binding sites to the N-terminal third of eIF4G.
The middle third region was shown to bind eIF4A and eIF3 (12), while the
C-terminal third region was shown to bind eIF4A (12, 14) and Mnk1 (26). See
Discussion section for explanations of models.
476 MORINO ET AL. MOL. CELL. BIOL.
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to eIF4G. However, if mTORC1 is reduced or inactivated through nutrient depletion or 
growth factor withdrawal, dephosphorylation of 4E-BP1 can occur. Unphosphorylated 
4E-BP1 then binds to eIF4E, ultimately it inhibits protein synthesis (144, 145). eIF4E 
binds to the mRNA cap and it binds to eIF4G on 43S for the cap-dependent translation.  
 
2.2.4.3 eIF4A  
eIF4A is a DEAD-box containing protein. A DEAD-box contains nine motifs, and 
one of them, motif II has amino acid sequence of asp (D)-glu (E) –ala (A)-asp(D), from 
where the name “DEAD” arises (146). Proteins containing DEAD-box participate in 
RNA metabolism (147).  eIF4A was the first DEAD box protein discovered.  It has an 
RNA dependent ATPase activity and ATP dependent RNA helicase activity: unwinding 
RNA secondary structure in 5’ untranslated region (UTR) and this facilitates ribosome 
access to the mRNA template (139, 148). If this helicase activity is inhibited, the small 
ribosome cannot scan on the mRNA. eIF4A has two binding sites in the middle one- third 
of eIF4G (4G-m, AA 672 to 970) and C-terminal one third of eIF4G (4G-C, AA 1201 to 
1411) (Fig 4). A mutated eIF4G which possessed eIF4E, eIF3 and eIF4A in middle one- 
third of eIF4G binding site, but not the C-terminal had 70% of 40S ribosome binding 
compared to control. However, mRNA translation occurred only 20-30% without C-
terminal compared to full length of eIF4G. This demonstrated that eIF4A binding site in 
the middle one- third of eIF4G is crucial whereas the site in the C-terminal is important to 
having a robust translation (140, 149).  
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2.2.4.4 PDCD4 
Abundance of PDCD4 is controlled by S6K1 and β-TrCP. Phosphorylation of 
PDCD4 by S6K1 at Ser 67 and ubiquitylation by the ubiquitin ligase β-TrCP lead to 
degradation of PDCD4 by proteasome (150). If phosphorylation does not occur, PDCD4 
binds to eIF4A and it prevents mRNA translation (5, 151, 152). As discussed earlier, 
eIF4A has 2 binding sites in eIF4G. PDCD4 binds eIF4G in the middle region 
independent of eIF4A. It was discovered by PDCD4 mutant inactivated for binding to 
eIF4A bound to the middle region of eIF4G. Therefore PDCD4 prevents eIF4A binding 
in C-terminal in eIF4G, which is not as crucial as the one in the middle, but important to 
have a robust translation (141). Not only eIF4G, but also PDCD4 contains alpha-helical 
MA-3 domains. eIF4G at C-terminal has MA-3 domain in the eIF4A binding domain, 
and PDCD4 contains two MA-3 domains at N and C terminals (149, 153, 154). The two 
MA-3 domains of PDCD4 are very similar in structure and function. They bind to eIF4A 
in N-terminal. If one of them is mutated, PDCD4 binding to eIF4A is decreased 
approximately 90%. The mechanism of inhibition of mRNA translation by PDCD4 is 
through both binding to eIF4A and binding to MA-3 domain in C-terminal in eIF4G. 
Therefore, the two domains working together make the binding to eIF4A to be tighter and 
stable, and PDCD4 also inhibits eIF4G binding to eIF4A as well (141, 149, 153, 155). 
 
 
 
2.3 Muscle differentiation: the role of mTORC1 
2.3.1 Muscle differentiation 
Adult skeletal muscle is a mature and stable tissue. It has the capacity to 
regenerate after injury or physical activity, particularly resistance training. This relies on 
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satellite cell activation, which posses the potential to differentiate into new fibers.  
Myogenesis, the process of generating muscle, begins at an early stage of embryonic 
development (131, 156). After birth, satellite cells act as muscle stem cells (157, 158).  
Satellite cells are so termed due to their location; quiescent satellite cells reside between 
the sarcolemma and the basal lamina. Up until the mature state, myogenic progenitor 
cells proliferate greatly until they reach the number of myonuclei and myofibrillar protein 
synthesis peak. Adult skeletal muscle fibers are terminally differentiated; therefore 
muscle repair and hypertrophy are accomplished by satellite cells. Satellite cells are 
normally in a non proliferative quiescence state. Once activated by extrinsic signals such 
as myotrauma, they proliferate. After proliferation, they either differentiate or withdraw 
from the cell cycle and return to a state of quiescence. If they differentiate, they fuse 
together to form new myofibers or fuse into existing myofibers and provide additional 
myonuclei to muscle fiber (159, 160). Satellite cell capacities are strongly related to 
protein expression.  
The molecular mechanisms regulating myogenesis are relatively well known. 
Myogenic differentiation 1 (MyoD), myogenic factor 5 (Myf-5), myogenin, and muscle 
regulatory factor 4 (MRF4) transcription factors are basic helix-loop-helix (bHLH) 
proteins. They are recognized as muscle regulatory factors (MRFs) and are also 
considered the driving force behind the specification and differentiation of all myogenic 
compartments (161). MyoD and Myf-5 are essential to establishing the myogenic cell 
lineage and producing committed undifferentiated myogenic stem cells. On the other 
hand, MRF4 and myogenin are critical to terminal differentiation events (162, 163). 
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2.3.2 mTORC1 and muscle differentiation 
Cell growth and proliferation are important factors in maintaining the proportions 
of organs. Even though most mitogens promote myoblast proliferation and inhibit 
differentiation, IGF-I and IGF-II stimulate both proliferation and differentiation in 
muscle cell culture (159). An effector of IGF-I, mTORC1 activity level was 10 times 
more during the differentiation of C2C12 and L6 muscle cells compared to proliferating 
cells (164, 165). In particular, N terminus of mTOR (residues 11-91, part of the first 
HEAT domain) is required for differentiation (165). mTORC2 component rictor 
downregulation suppressed myoblast fusion through downregulation of AKT Ser 473 
phosphorylation. As mentioned earlier, AKT Ser 473 phosphorylation is important for the 
activation of mTORC1 (166). 
Earlier studies in Drosophila showed that inactivation of dTOR or its substrate 
dS6K1 cause a high rate of embryonic lethality, reduction of cell size and body size (85, 
167). Later, studies in mammalian system showed that mTORC1-knockout embryonic 
mouse had a proliferation of cell lesions and the inability to have embryonic stem cell. In 
stem cells, an mTORC1 inhibitor slowed the rate of proliferation and showed 
undifferentiated condition, and rapamycin resistant mutant mTOR gene conserved the 
cell size (104, 167-169). Overexpression of either S6K1 or eIF4E increased cell size, and 
co-overexpression of those genes further increased cell size (169). On the other hand, 
mutations of phosphorylation site in 4E-BP1, which did not lose binding capacity to 
eIF4E, prevented mRNA translation initiation activities and reduced the cell size (169). 
Those studies showed that mTORC1 and its downstream targets regulate the cell size. In 
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vivo, skeletal muscle activation relies on satellite cell activation, proliferation and 
differentiation.  
On the other hand, in cell culture, differentiation occurs after growth factors are 
removed. Not only C2C12, but also various myoblast cells treated with rapamycin had 
differentiation inhibited (164). C2C12 transfected with rapamycin-resistant mTOR 
retained the ability to differentiate even in the presence of rapamycin. Nutrient dependent 
IGF-II is an important factor in myogenesis at the onset of myoblast differentiation. 
However activities of mTORC1 or S6K1 activities are necessary at the myotube 
maturation stage (170). 
 
2.3.3 The role of PDCD4 in differentiation and apoptosis 
PDCD4 gene (also known as Dug, H731, TIS and MA-3) was initially found as an 
apoptotic gene.  It was upregulated during apoptosis and identified in mice in 1995 (171-
173). The gene expression of PDCD4 is found not only in vertebrates but also in 
Drosophila melanogaster (151, 152). It implies that PDCD4 has been highly conserved 
during evolution and it also implies an important function for this protein (151, 174). It is 
expressed in a wide variety of tissues and at the highest level in the liver and to a lesser 
extent in the heart and skeletal muscle in mouse (171, 172, 175).  
PDCD4 expression is normally at low level, however apoptosis upregulates its 
expression (171, 175-177). PDCD4 has a nuclear localization signal (NLS) at its N and C 
termini. It shuttles between the nucleus and cytosol (5, 178-180). PDCD4 localizes 
primarily in the nucleus. It can be exported from the nucleus to the cytosol under certain 
condition such as serum withdrawal (151, 172, 180). However, this observation is 
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dependent on cell type and cell conditions. In general, PDCD4 localization is in the 
nucleus in normal tissue and shuttle to cytoplasm in carcinoma tissue (172, 181, 182). 
However in breast tissue, PDCD4 is predominantly expressed in the cytoplasm in normal 
condition, but in nucleus in breast cancer cell (183).  
The roles of PDCD4 in the cytosol are well documented: contribution for 
transcription and translation (152, 172). PDCD4 may have a role in the nucleus, however 
this is not clear. It might be a contributor for nuclear RNA processing events such as 
splicing and nucleo-cytoplasmic transport (151, 172, 180, 183). A loss of PDCD4 
expression or accumulation of PDCD4 in the nucleus may positively regulate cell 
proliferation (183) 
Programmed cell death, referred to as apoptosis, is a cellular homeostatic 
response. Apoptosis serves to eliminate unwanted or damaged cell for normal 
development of multicellular organisms. Proliferating myoblasts in culture cells withdraw 
from the cell cycle once the medium is changed to one with low concentration of 
mitogens. Those cells undergo either differentiation or apoptosis.  
There is some evidence that PDCD4 may regulate other cell cycle regulator (184). 
p21 inhibits cyclin-dependent kinase4/6 and the transcription of the mitosis promoting 
factor CDK1/cdc2 (184). The expression of p21 was correlated with apoptosis-resistance 
condition. Moreover, overexpression of p21 can protect from apoptosis during myocyte 
differentiation (185).  PDCD4 is known as an upregulator of p21. p21 is an important 
factor for differentiation (186). Since PDCD4 upregulates it, this implies that PDCD4 
may have a role during muscle differentiation.  However, this observation is also cell 
specific and cannot be generalized (172). 
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The serine/threonine kinase AKT controls cellular processes such as cell 
proliferation, growth and survival through phosphorylation of numerous downstream 
substrates (180). AKT is also considered as an anti-apoptotic regulator, and PDCD4 
phosphorylation by phosphorylated AKT may have a role in differentiation (182). 
Phosphorylation of PDCD4 at Ser 457 by activated AKT causes nuclear localization 
(180, 182). In colorectal cancer, phosphorylated AKT is correlated with the loss of total 
PDCD4 expression and with the less localization from nucleus to cytoplasm (182). 
In caspase-dependent apoptotic pathway, caspase-3 is the executioner caspase. 
Activated caspase-3 translocates to nucleus and induces DNA fragmentation (187). 
Inhibition of caspase 3 activity reduces myoblast fusion and myotube formation (188). 
The PDCD4 accumulation in nucleus correlated to apoptosis in human hepatocellular 
carcinoma. This is because its nuclear accumulation was observed in nuclear fragmented 
cells (189). PDCD4 activates Bax and release cytochrome C from the mitochondria. This 
leads to caspase-dependent apoptosis (187). However the mechanism by which PDCD4 
activates, Bax has not yet been elucidated (178, 189). 
Recently, apoptotic cells have been shown to be promoters of myotube formation 
(4). As the name suggests, programmed cell death 4 (PDCD4) is pro-apoptotic and it may 
regulate myotube formation. Therefore it may have the potential for a therapeutic 
approach to muscle degenerating conditions.  
 
2.4 PDCD4 research 
2.4.1 PDCD4 in cancer research 
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Events leading to apoptosis are important to understand cancer development 
(174). As an apoptotic gene, PDCD4 is studied as a tumor suppressor in cancer research 
(5, 172, 190, 191).  
PDCD4 inhibits tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA)-
induced neoplastic transformation (189, 192). Reduced PDCD4 expression was observed 
in neoplastic transformation sensitive cells; on the other hand, its expression was high in 
neoplastic transformation resistant cells (193). PDCD4 expression is reduced in human 
tumors (178, 189, 194). PDCD4-deficient mice developed spontaneous lymphomas and 
had a significant shorter life span (195) and the overexpressing PDCD4 rescued cell 
transformation (196). 
In cancer progression, upregulation of transcription factor is an important factor. 
Nuclear factor kappa-light chain-enhancer of activated B cell (NF-kB) and activated 
protein-1 (AP-1) are known as those transcription factors. PDCD4 inhibits the AP-1 
dependent transcription, but not NF-kB (197, 198). AP-1 promotes cell proliferation 
(154, 178), and it is recognized as a target of mitogen activated protein kinases (MAPK) 
(199, 200). PDCD4 does not inhibit c-Jun, which is a component of AP-1 or c-Jun 
activator Jun N-terminal Kinase (JNK) directly (201, 202). Instead, PDCD4 inhibit JNK 
upstream kinase mitogen activated protein kinase kinase kinase kinase 1 (MAP4K1). This 
ultimately inhibits AP-1 dependent transcriptions (152, 155, 197, 202).  
PDCD4 is a translation initiation inhibitor. It binds to eIF4A and inhibits the 
formation of eIF4F complex, a complex that is required for mRNA translation initiation. 
As explained earlier, phosphorylation (inactivation) of PDCD4 promotes cell growth. In 
cancer cells, inactivated PDCD4 promotes cancer development. Therefore, an 
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overexpression PDCD4 induced apoptosis of cancer cells. To induce apoptosis and arrest 
cell cycle in cancer cells may be the most efficient way to deal with tumor progression 
(203).   
Also, related to cancer, PDCD4 is a target of micro RNA21 (miR-21) (152, 202). 
A microRNA is a short noncoding RNA, which regulates gene expression post 
transcriptionally (204). MiR-21 is upregulated in most malignant cancers and cardiac 
disease (205, 206). The targets of miR-21 are tumor suppressors, including PDCD4. 
MiR-21 inhibition may be a potential therapeutic target to prevent PDCD4 reduction in 
cancer cells (205). 
 
2.4.2PDCD4 in muscle research 
Muscle formation and protein synthesis have a correlative relationship. In skeletal 
muscle, mTORC1 and its substrate S6K1 are known regulators of mRNA translation and 
protein synthesis (207). However the mechanisms by which S6K1 regulates protein 
synthesis are not clearly documented in muscle studies. Since PDCD4 inhibits mRNA 
translation, it is an important factor to regulate protein synthesis. The first PDCD4 
research in muscle was done by Zargar et. al. in 2011. In a study with rat, starvation 
decreased phosphorylation of PDCD4 along with a reduction in protein synthesis in 
skeletal muscle. Conversely, total PDCD4 was increased. Those effects were reversed 
once the rats were refed. In vitro, when myoblasts depleted of PDCD4 were grown in 
amino-acids and serum free medium, those cells incorporated twice as much 
phenylalanine into proteins than control cells. This showed that PDCD4 is sensitive to 
nutrients, and PDCD4 inhibits protein synthesis (208). However this did not examine the 
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relationship between mTORC1/S6K1 and PDCD4. In a follow-up study, it was shown 
that total PDCD4 expression, but not phosphorylated PDCD4, is sensitive to the medium 
nutrient composition. PDCD4 expression was abundant if cells were in the starvation 
medium or incubated with rapamycin (mTORC1 inhibitor) or MG132 (proteasome 
inhibitor). In the refeeding stage, they also compared the stimulus. Further experiments 
showed that in muscle cells, serum, but not amino acids, promote PDCD4 proteolysis. 
Therefore, growth factor is the definite regulator of PDCD4 expression (209). Data 
implicating apoptosis in the regulation of muscle cell differentiation prompted me to 
examine whether PDCD4, a proapoptotic protein may regulate skeletal muscle cell 
differentiation. 
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3.1 Rationale 
 PDCD4 is known to reside predominantly in the nucleus in proliferating cell, and 
it shuttles to cytosol under serum withdrawal (151, 172). However, this effect depends on 
the cell type and their growth state (151). Because transition from proliferating to 
differentiating myoblasts is initiated by a reduction of serum quality and concentration, 
this transition may be regulated by PDCD4. 
PDCD4 is known as an mRNA translation inhibitor. When cells are proliferating, 
PDCD4-depleted-cells had more protein synthesis compared to the control. However, the 
opposite phenomenon was observed in myotubes: PDCD4-depleted myotubes had less 
protein synthesis (208, 209). Thus, this implies PDCD4’s involvement in myotubes 
metabolism may be different from that of myoblasts.  
Apoptotic cells are known to be a regulator of satellite cell fusion to form new 
muscle (4), and PDCD4 is a pro-apoptotic protein.  PDCD4 is an upregulator of p21, 
which is an important factor for differentiation (184). 
 
3.2 Objectives 
1. Examined expressions of protein and mRNA level of PDCD4 during  
   skeletal muscle cell differentiation.	 	 	      
2. Examined the effect of PDCD4 depletion on myoblast fusion. 
  3. Examined the effect of overexpression of PDCD4 during muscle cell  
     differentiation. 
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3.3 Hypothesis 
1. I hypothesized that PDCD4 expression would be high on Day 1 compared to Day 
0, since withdrawal from the cell cycle is a stressor for cells.  
2. I hypothesized that PDCD4 expression in the nucleus would be lower and it 
would shuttle to the cytosol after medium is changed from growth medium to 
differentiation medium.  
3. Because apoptosis is required for myotube formation and PDCD4 is a pro-
apoptotic protein, depletion of PDCD4 would lead to impaired myotube 
formation. 
4. I hypothesized that overexpression of PDCD4 would induce myotube formation. 
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Introduction 
Maintaining skeletal muscle mass is a crucial factor in human health for people of 
all ages. The maintenance of muscle mass is essential for mobility, disease prevention 
and quality of life, since muscle mass comprises approximately 40% of the average adult 
body weight (1). In general, the mammalian body maintains a balance of protein 
synthesis and degradation. If protein synthesis exceeds protein degradation, it leads to 
muscle hypertrophy. On the other hand, protein degradation exceeds protein synthesis, 
muscle wasting (atrophy) can occur (9). 
The mammalian/mechanistic target of rapamycin complex 1 (mTORC1) is well 
known to be a regulator of muscle mass autophagy (78-80). The importance of its 
downstream substrate S6 ribosomal protein kinase 1 as a regulator of mRNA translation 
and as an inhibitor of insulin receptor substrate 1 (IRS-1) is also well documented. 
However little is known about their roles and significance in muscle differentiation and 
myogenesis. Programmed cell death 4 (PDCD4), a downstream substrate of S6K1 was 
discovered to be upregulated in apoptotic cells (149). There is evidence that apoptosis is 
required for muscle cell differentiation (7). PDCD4 has been extensively studied as a 
tumor suppressor and an mRNA translation inhibitor in many different cells in cancer 
research, however its role in skeletal muscle cells has not been elucidated. Therefore, the 
objectives of this study were to examined expressions of protein and mRNA level of 
PDCD4 during skeletal muscle cell differentiation. Also, examined the effect of PDCD4 
depletion on myoblast fusion and the effect of overexpression of PDCD4 during muscle 
cell differentiation. 
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Materials and methods 
Reagents: Fetal Bovine Serum (FBS), Horse Serum (HS), Lipofectamine RNAimax, 
Lipofectamine 2000 DNA Transfection Reagent, Optimem medium, and 
antibiotic/antimycotic (Ab-Am) reagents were purchased from Life Technologies 
(Burlington, Ontario, Canada). PDCD4 siRNA oligonucleotides were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Phosphatase and protease inhibitor cocktails were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  α- Modification of Eagle’s 
Medium (AMEM) and Phosphate Buffered Saline (PBS) were obtained from Wisent (St-
Bruno, Quebec, Canada).  
Antibodies: Antibodies to PDCD4 (cat #9535) and GAPDH (cat #2118) were purchased 
from Cell Signaling Technology (Danvers, MA). Antibodies to troponin, myogenin and 
MHC-1 were purchased from Developmental Studies Hybridoma Bank (Iowa City, Iowa, 
USA). Antibodies to γ-tubulin were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  
Cell culture and Treatments: Differentiation experiments were performed as follows: L6 
rat skeletal muscle myoblasts were obtained from the American Type Culture Collection. 
Stocks of the earliest passage cells have been stored and used. The cells were cultured in 
6 well-plates (150 x 103 cells/well for differentiation experiments or PDCD4 
overexpression experiments and 250 x 103 cells/well for PDCD4 siRNA experiments) or 
in 10cm plates (600 x 103 cells/plate). The cells were propagated at 37°C and 5% CO2 in 
humidified atmosphere in complete proliferation medium composed of AMEM 
supplemented with 10% FBS, 1% Ab-Am until they reached 80-90% confluency. Cells 
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were then shifted into differentiation medium (DM) which is AMEM supplemented with 
2% HS and 1% Ab-Am.  
Cell Fractionation: Twenty-one 10 cm plates (3 plates per day) were used for this 
experiment. After they reached up to 80-90% confluency, the plates for day 0 were 
harvested following the procedure below. The medium for the remaining plates was 
changed to DM. The DM was changed every forty-eight hours. Remaining plates were 
harvested Day 1 to Day 6. To harvest the cells, they were trypsinized with 1 ml/10cm- 
plate. Five mls of ice cold PBS were added to stop the trypsin and the cells put in 15 ml 
tubes. They were centrifuged at 621.6g (2000 rpm) for 5 minutes in a microcentrifuge. 
After the centrifugation, the PBS was sucked out, and 1 ml PBS was added and cells were 
resuspended. Everything was put in 1.5 ml eppendorf tubes and centrifuged 431.74g 
(2300 rpm) for 3 minutes at 4°C in a microcentrifuge. PBS was then removed. Five 
hundred µl of Buffer 1 (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 
10 µl/ml protease inhibitor and 10 µl/ml phosphatase inhibitor) were added to the pellet 
and resuspended. The samples were put on ice and vortexed for 15 sec every minute for 5 
mins at low speed. From the resulting lysate, 100 µl aliquot was put in eppendorf tubes 
for further examination. The remaining volume was centrifuged 431.74g (2300 rpm) for 3 
minutes at 4 °C in a microcentrifuge. After centrifugation, the supernatants were 
collected as cytosol. To make sure there was no contamination, samples were washed 2 
times with 200 µl Buffer 1. After the wash, the pullet was resuspended in 150 µl of 
Buffer 2 (50 mM Tris, pH 7.4, 5 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 40% 
(wt/vol) glycerol, 10 µl/ml protease inhibitor and 10 µl/ml phosphatase inhibitor). This 
was the nuclear fraction.  
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35S-Methionine Pulse-Chase and Immunoprecipitation experiments: Twenty-one 10 
cm-plates (3 plates harvested at each time point) were used for this experiment. Twenty-
four hours after cells were plated, the medium for twenty-one plates was changed to 4 mL 
of GM and 30 µCi of [35S] methionine/cystine. Twenty-four hours after adding 
radioactive methionine (48 hours after seeding cells), GM and 30 µCi of [35S] 
methionine/cystine were removed. Plates were rinsed in PBS and harvested or incubated 
in DM supplemented with methionine/cysteine (2 mM). Medium was changed every 4 
hour till harvested. For harvesting, all plates were washed twice with ice cold PBS and 
harvested with 450 µl/plate of 3-[(3-cholamidopropyl) dimethylammonio]-1-
propanesulfonate (CHAPS) Buffer (40 mM HEPES pH 7.5, 120 mM NaCl, 1mM EDTA, 
10 mM Pyrophosphate, 10 mM Glycerophosphate, 50 mM sodium fluoride (NaF), 0.5 
mM Orthovanadate) with supplementation (0.3% CHAPS, 1 mM DTT, 1 mM 
Benzamidine (Benz), 0.5 mM sodium vanadate (Nav), 10 µl/mL of protease inhibitor, 10 
µl/mL of phosphatase inhibitor, 6.25 mM NEM). Lysates were put in eppendorf tubes 
(this is the LOAD). New tubes were prepared for immunoprecipitation (IP). To do this, 
400 µl of CHAP buffer, 3 µl of anti-PDCD4 antibody (Cell Signalling cat #9535) and 
300 µl lysate were added. Those tubes were incubated overnight in the cold room (4°C) 
with rotation. The following day, magnetic beads solution was prepared. BioMag Protein 
G (QIAGEN, cat #311812) was used (100 µl/tube). The re-suspended beads (100 µl) 
were washed 3 times in Low Salt Buffer (LSB: 20 mM TrisHCl, 150 mM NaCl, 5 mM 
EDTA, 0.5% Triton X-100, 0.1% β-mercaptoethanol). After washing, the beads were 
resuspended in 100 µl/tube of LSB+ (LSB supplemented with: 1 mM DTT, 0.5 mM Nav, 
1mM Benz, protease inhibitor 10 µl/ml, phosphatase inhibitor 10 µl/ml, 6.25 mM NEM 
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and 0.1% milk powder). After adding LSB+, the tubes were incubated for 2 hours in the 
cold room (4°C) with rotation. After the incubation, samples were put on the magnetic 
rack. Supernatant was collected. After taking out the supernatant, each sample was 
washed twice with 500 µl of LSB+ and washed once with High Salt Buffer (HSB: 50 
mM TrisHCL, 500 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, 0.04% β-mercaptoethanol) with supplementation (1 mM DTT, 
0.5 mM Nav, 1mM Benz, protease inhibitor 10 µl/ml, phosphatase inhibitor 10 µl/ml, 
6.25 mM NEM). After removing the washes, 100 µl of 1x Sample Loading buffer 
supplemented with β-mercaptoethanol were added to each tube. They were vortexed and 
boiled for 5 mins at 95°C. They were vortexed again, and centrifuged for 2 mins at 
13000g. Samples were placed on the magnetic rack and supernatant was transferred into 
1.5 ml eppendorf tube (eluate). 
RNA Interference: To knockdown PDCD4, siRNA oligonucleotides were used. L6 
myoblasts (250 x 103 cells) were seeded in 6-well plates. The cells in the negative control 
condition were transfected with a scrambled RNAi oligonucleotide that will not induce 
the knockdown of any rat proteins. The PDCD4 #1 siRNA oligonucleotide (Sigma-
Aldrich): PDCD4 #1 sense (GUCUUCUACUAUUACCAUA [dT] [dT]), PDCD4 #1 
antisense (5′UAUGGUAAUAGUAGAAGAC [dT] [dT]), PDCD4 #2 sense 
(CUACUAUUACCAUAGACCA [dT] [dT]), and PDCD4 #2 antisense 
(UGGUCUAUGGUAAUAGUAG [dT] [dT]) were used at a final concentration of 30 
nM, following the manufacturer’s protocol. After forty-eight hours of incubation with the 
transfection mix, cells were harvested or switched to DM. They were harvested in lysis 
buffer (25 mM Tris, pH 7.5, 1 mM EDTA, 2% sodium dodecyl sulfate (SDS) 
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supplemented with protease inhibitor cocktail (10 µl/ml), phosphatase inhibitor cocktail 
(10 µl /ml) and DTT 1M (1 µl /ml) from day 0 through day 5. Cell lysates were passed 
through a 25-gauge needle to break apart the globular proteins and collected in 1.5 ml 
eppendorf tube. 
mRNA expression experiment: The cell preparation is the same as above as for cells 
transfected with siRNA oligonucleotide. On the day of harvesting, cells were harvested 
and RNA was extracted by TRIzol Plus RNA Purification Kit (Life Technologies, 
Burlington, Ontario, Canada) following the manufacturer’s protocol. After the extraction, 
RNA concentration was measured by Smart SpecTM Plus (Bio-Rad Laboratories 
((Canada)) Ltd Life Science Group).  
Reverse transcription (RT) was done with iScript Advanced cDNA Synthesis Kit 
for RT-qPCR (Bio-Rad Laboratories ((Canada) Ltd Life Science Group) following the 
manufacturer’s protocol. RT reaction was carried out for 60 minutes at 42 °C followed by 
5 minutes at 85 °C in 5345 PCR Mastercycker, Gradient Thermal Cycler (Eppendorf) 
Resulting cDNA was diluted 1.5 times with autoclaved deionized water. In carrying out 
quantitative PCR (qPCR), the following primers were used:  
	  
primer 
	  
PDCD4 forward  ATGAGACTGTGGTTCTGCCC 
reverse TCCCTTAACATCTCCGCGAC 
Myogenin forward  CCCAGTGAATGCAACTCCCA 
reverse CGAGCAAATGATCTCCTGGGT 
Myosin 
Heavy Chain 
forward  GAGTCCCAGGTCAACAAGCTG 
reverse GTGCCTCTCTTCGGTCATTC 
HPRT forward  CTTCCTCCTCAGACCGCTTTT 
reverse ATCACTAATCACGACGCTGG 
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All primers were purchased from Life Technologies (Burlington, Ontario, Canada). 
qPCR was conducted with 10 µl of SsoAdvanced Universal SYBR Green Supermix (Bio-
Rad Laboratories ((Canada)) Ltd Life Science Group), 1.25 µl of 10  µM of each forward 
and each reverse primer, 6 µl autoclaved deionized water and 1.5 µl of diluted cDNA. 
qPCR products and data were obtained by CFX9TM  Real-Time System C1000 Thermal 
Cycler and CFX Manager 3.1 (Bio-Rad Laboratories ((Canada) Ltd Life Science Group).    
Overexpression experiment:  To overexpress PDCD4, EGFP-empty and EGFP- PDCD4 
plasmid were used. Plasmid pcDNA3-EGFP was a gift from Dr Doug Golenbock 
(Addgene plasmid # 13031), 1436 pcDNA3 Flag HA from Dr William Sellers (Addgene 
plasmid # 10792), and pGEX6p1-hPdcd4 from Dr Haiwei Song (Addgene Plasmid 
#20693). Human PDCD4 was digested with Bamh1 and Xho1 from pGEX6p1-hPDCD4 
and cloned into the BamH1 and Xho1 sites in pcDNA3 Flag HA or pcDNA3-EGFP to 
generate, respectively PDCD4 Flag pcDNA or PDCD4 EGFP pcDNA plasmids. The 
integrity of these resulting plasmids was confirmed by PCR, restriction digestion and 
sequencing different regions of the plasmids. L6 myoblast (160 x 103 cells) were seeded 
and transfected in 6-well plates when the wells were 70-75% confluency. Plasmid was 
used at 2.5 µg per well. After forty-eight hours of incubation with the transfection mix, 
cells were harvested or switched to DM. They were harvested in lysis buffer from day 1 
through day 5 of differentiation in DM. Cell lysates were passed through a 25-gauge 
needle to break apart the globular proteins and collected in 1.5 ml eppendorf tube. 
Western blot determination for all experiments: For experiments involving nuclear-
cytosolic fractionation, 30 µl (nuclear fraction) or 25 µl (each of cytosol and whole cell 
lysate) samples were loaded per well of 15% SDS-polyacrylamide gel electrophoresis 
	   42	  
(PAGE). For immunoprecipitation experiments, 20 µl (load) or 30 µl (eluate) samples 
were loaded per well of 10% gel. For RNAi experiments, protein concentration was 
determined by Pierce BCA Protein Assay Kit (Thermo Scientific, IL, USA). Equal 
amounts of protein (25 µg) were loaded per well of 12.5% gel. Proteins were then 
transferred onto polyvinylidene difluoride (PVDF) 0.2 µm membrane. Membranes were 
subsequently blocked in 5% non-fat milk in Tris-Buffered Saline + Tween20 (TBST) for 
1 hour at room temperature. After 1 hour, membranes were washed quickly twice and 
then washed 3 times for 5 min with TBST, and then incubated with the diluted desired 
primary antibody (PDCD4: 1:2000 for all experiments; histone H2A: 1:1000 for nuclear 
loading control; GAPDH: 1:1000 for cytosolic loading control; MHC-1, troponin and 
myogenin: 1:500 for RNAi experiments, γ–tubulin: 1:10,000 for loading control except 
for nuclear and cytosol). All the primary antibodies were diluted with 2.5% Bovine 
Serum Albumin (BSA) in TBST. Following overnight incubation in the cold room (4°C), 
membranes were washed quickly twice and then washed 3 times for 5 minutes with 
TBST, and incubated with HRP-conjugated goat anti rabbit (GAR) (for PDCD4, 
GAPDH, histone H2A) or goat anti mouse (GAM) (for MHC-1, myogenin, troponin and 
γ–tubulin) secondary antibodies for 1 to 3 hours at room temperature. Immunoblots were 
then incubated with the Immobilon Western Chemiluminescence HRP Substrate  
(Millipore). 
For visualizing, the Kodak imaging station (Molecular Imaging System 
Carestream Health Inc.) was used. For the immunoprecipitation experiment only, 
membranes were exposed to High performance chemiluminescence film (GE Healthcare 
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Limited) for 48 hours. Signals were quantified using the Carestream Molecular Imaging 
software (Version 3, Software, La Jolla CA).  
Statistical Analyses: Data are presented as means ± SD of all experiments. One-way 
analysis of variance (ANOVA) was used, followed by Tukey’s post-hoc tests to assess 
statistically significant differences amongst means. The level of significance was set at 
p<0.05 for all analyses. Statistical analyses were done using GraphPAD (Version 3, 
GraphPAD Software, La Jolla, CA, U.S.A.).  
Results 
PDCD4 expression increases during C2C12 and L6 cell differentiation. 
PDCD4 expression in L6 (Fig 1) and C2C12 (Fig 2) was significantly increased at 
the onset of differentiation (p<0.05) after medium was changed to differentiation medium 
(Fig 1A, B, Fig 2A, B). MHC-1, as a myotube formation marker, expression was 
observed starting Day 3 in L6 cells (Fig 1C), Day 2 in C2C12 cells (Fig 2C). Significant 
difference started D4 in L6 cells, Day 3 in C2C12 cells (p<0.05). 
 
Nuclear-Cytosolic expression of PDCD4 during the skeletal muscle cell 
differentiation. 
 PDCD4 is known to shuttle between the nucleus and cytosol. To examine nuclear-
cytoplasmic distribution of PDCD4 during differentiation, I fractionated L6 (Fig 3) and 
C2C12 (Fig 4) cell lysate. Western blots and graphical representation of nuclear and 
cytoplasmic expression of PDCD4 during differentiation are shown in Fig 3 and Fig 4. In 
general, PDCD4 expression is high in nucleus in proliferating cells. In muscle cells, 
PDCD4 expression was low in lysate from myoblast, however, expression was observed 
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in nucleus and cytosol on day 0 in both L6 (Fig 3) and C2C12 (Fig 4). The cytosolic 
expression was higher than nuclear one (Fig 3, 4). At the onset of differentiation, 
cytosolic expressions were high, which was expected. On the other hand, unexpectedly, 
nuclear expressions remained higher on D1 to D6 compared to day 0. Cytosolic 
expression of PDCD4 was significantly higher on day 1 compared to day 0 (p<0.05) in 
both C2C12 and L6 muscle cells (Fig 3C, 4C). 
 
PDCD4 abundance during differentiation is regulated by proteolysis 
To figure out why PDCD4 expression is higher on day 1 and day 2 of 
differentiation (Fig 1, Fig 2), I used pulse chase technique to examine whether the 
changes were due to changes in PDCD4 degradation. In particular, in 
immunoprecipitation for 35S-labeled cells, there was a significant decrease in PDCD4-
associated radioactivity between 0H and 8H vs. 32H after the medium change to DM 
(p<0.05) (Fig 5B, C). On the other hand, mRNA expression of PDCD4 showed that there 
was a significant difference between D0 and D2 (Fig 7A of CTL). 
  
Knockdown of PDCD4 in L6 myoblasts leads to significant changes in myotube 
formation.  
To examine the role of PDCD4 during myotube formation, I employed RNA 
interference (RNAi) mediated knockdown of the protein. Western blot analysis showed 
that PDCD4 depletion was conducted successfully (Fig 6A, B). From day 3, cells 
transfected with the control siRNA started to differentiate as can be seen in MHC-1 
expression (Fig 6A, C). This was observed much less in PDCD4-depleted-cells (Fig 6C).  
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The myofibullar proteins (MHC-1 and myogenin expressions) were higher in the 
control compared to PDCD4-depleted-cells at all time points (Fig 6C, D). However 
MHC-1 mRNA expression was not different between treatments (Fig 7B). The 
morphological image showed that PDCD4-depleted-cells had very few and smaller 
myotubes (Fig 6E, on the bottom right).  
 
Overexpression of PDCD4 in L6 myoblast leads to increased myotube formation 
The knockdown experiment showed the importance of PDCD4 in myotube 
formation (Fig 6). Therefore, I overexpressed PDCD4 in L6 cells (Fig 8B, C) and 
observed more myotubes formation (Fig 8A, B and D) (p<0.05). Morphologically, cells 
overexpressing PDCD4 appeared to have more myotubes compared to control (Fig 8A). 
The transfection of efficacy was low (approximately 20%). Nethertheless, I observed 
more myotube formations in transfected cells (Fig 8A). 
 
Discussion 
Regulation of mRNA binding to 40S ribosomal subunit is the initial step of 
protein synthesis (138). The mRNA binding is regulated by mTORC1 signalling 
pathway. It does this via at least two of its substrates, 4E-BP1 and S6K1. mTORC1 
phosphorylates  4E-BP1 and S6K1 directly. The phosphorylated 4E-BP1 dissociates from 
eIF4E. The activated S6K1 phosphorylates PDCD4. The phosphorylated PDCD4 is 
subsequently degraded by proteasome via ubiquitylation by E3 ligase β-TrCP (150). 
PDCD4 binds to and inhibit eIF4A. Phosphorylation of PDCD4 frees eIF4A. eIF4E and 
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eIF4A are components of eIF4F, a complex needed to initiate mRNA translation (141, 
198, 201). 
PDCD4, a pro-apoptotic protein, is also known as a tumor suppressor protein (5, 
172, 190, 191). Tumor promoters such as TPA or Epidermal growth factor (EGF) induces 
neoplastic transformation through increasing the expression of transcription factors such 
as NF-kB and AP-1 (189, 192). PDCD4 inhibits AP-1 dependent transcription by 
inhibiting MAP4K1, which is upstream of AP-1 (197, 198). Therefore, PDCD4 inhibits 
TPA-induced neoplastic transformation by inhibiting AP-1 activation (189, 192). This is 
the main idea of PDCD4 related cancer research, however the role in muscle research is 
not well established yet. The ability of PDCD4 to inhibit the cell cycle and to promote 
apoptosis led me to examine its role in regulating muscle cell differentiation. PDCD4 is 
expressed in a wide variety of tissues and at the highest level in the liver and to a lesser 
extent in the heart and skeletal muscle in mouse (171, 172, 175). In both L6 and C2C12 
cells, the expression of PDCD4 was low during proliferation (D0) (Fig 1A, B and 2A, B). 
Beginning of differentiation (D1-2), PDCD4 expression increased significantly. Previous 
studies showed that PDCD4 expression is normally at low level, however apoptosis or 
transformation upregulates its expression (171, 175-177).  PDCD4 expression is high in 
non-proliferating cells such as differentiating cells (151). Those observations are 
consistent with our observation in muscle cells. 
PDCD4 has a nuclear localization signal (NLS) at its N and C termini. It shuttles 
between the nucleus and cytosol (5, 178-180). There are many studies showing the 
movement of this protein, however they are controversial. The reason is that each tumor 
cell is unique, and depending on the stage of the progression of the cancer the 
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characteristics can vary. Studies demonstrated that PDCD4 expression is predominantly 
in the nucleus in proliferating cells. It can be exported from the nucleus to the cytosol 
under certain condition such as serum withdrawal (151, 172, 180). However, this 
observation is dependent on cell type and cell conditions. For example, PDCD4 is 
predominantly expressed in the cytoplasm in breast cancer cell (183). In muscle cells, 
PDCD4 shuttling is not the same as in majority of cancer cells: cytosolic expression was 
higher in proliferating cells (Fig 3C, 4C), and nuclear expression was observed in 
differentiating cells (Fig 3B, 4B). Also both cytosolic and nuclear expressions in 
differentiating cells were higher than in proliferating cells (Fig 3B,C and Fig 4B,C). It 
may imply nuclear PDCD4 involvement in nuclear RNA processing events such as 
splicing and nucleo-cytoplasmic transport (151, 172, 180, 183). A loss of PDCD4 
expression or accumulation of nuclear PDCD4 may positively regulate cell proliferation 
(183). PDCD4 is upregulated in apoptotic cells (171-173). The apoptotic protein may 
have a role in forming myotubes (4). Increased expression of PDCD4 in the nucleus may 
inhibit myotubes formation. However those observations were not clear in this study. 
Protein abundance depends on the balance between protein synthesis and 
degradation. To understand the mechanism of PDCD4 expression at the onset of 
differentiation, I used the pulse chase assay (Fig 5A). There	   are	   different	   ways	   to	  examine	   PDCD4	   degradation.	   PDCD4 phosphorylation is regulated by its upstream 
kinases S6K1 and AKT. Phosphorylation of PDCD4 on Ser 457 by AKT may have a role 
in nucleus, but this is not conclusive in literature (182). PDCD4 phosphorylation on Ser 
67 by S6K1 is subsequently degraded by proteasome through ubiquitylation by E3 ligase 
β-TrCP. The phosphorylation of Ser 67 promotes phosphorylation on Ser 71 and Ser 76 
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allowing for binding to β-TrCP (178). Therefore, we could use the anti-phPDCD4  
antibodies to measure the amount of PDCD4. This is an indirect way of looking at 
PDCD4 degradation. Even though phospho-PDCD4 antibodies are available on market, 
they are unreliable. Instead, I used anti-β-TrCP (cell signalling cat #4394) to examine 
regulation of PDCD4 degradation. The data showed β-TrCP expression is low during cell 
proliferation (supplemental figure 1A, B). It makes sense since PDCD4 expression is low 
during cell proliferation. During differentiation, β-TrCP expression is significantly higher 
at any day point compared to cells in proliferation. This implies that PDCD4 abundance 
during differentiation is regulated by proteolysis (supplemental figure 1A, B). However, 
if degradation of PDCD4 is rapid, one might not be able to see ubiquitylated PDCD4. If 
degradation occurs very quickly, one may not be able to see ubiquitylated proteins (210). 
An increase in β-TrCP should correspond to increased ubiquitylation of PDCD4 and 
therefore increased degradation of PDCD4. However this is not a direct measure of 
protein degradation. β-TrCP has many substrates. For example, one of the important 
components of mTORC1, DEPTOR, is also a substrate of β-TrCP (101, 106, 211). To 
strengthen my analysis of degradation, I used pulse chase assay combined with 
immunoprecipitation. Because PDCD4 expression is low during proliferation (when I 
labeled cells with the radioactive isotope), I immunoprecipitated samples. Results from 
the pulse chase assay and immunoprecipitation experiments indicated that the decrease in 
PDCD4 abundance as differentiation progressed might be due to increased proteolysis 
(Fig 5B, C). However, mRNA levels of PDCD4 also significantly increased between D0 
and D2 (Fig 7A of CTL). Taking together, these imply that PDCD4 abundance during the 
onset of differentiation is due to the increases of both protein synthesis and degradation. 
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To examine the significance of PDCD4 expression during differentiation, I used 
RNAi to deplete the protein in differentiating cells. Results with siRNA experiment 
showed that the expression of myotube formation indicators (MHC-1, myogenin) was 
less in PDCD4-depleted-cells. It may imply that the expression of PDCD4 is an important 
factor for muscle cell to form myotubes. Further assessment, mRNA expression was 
measured. The myogenin mRNA expression showed that mRNA expression in control 
condition was significantly higher than in cells depleted of PDCD4 at any day points (Fig 
7C). The same trend was observed in protein expression (Fig 6E). In control (scrambled) 
cells, myogenin mRNA expression peaked on Day 2 and decreased by Day3 and Day4. In 
PDCD4 knocked-down cells, myogenin expression increased during differentiation. This 
observation is consistent with the literature: myogenin mRNA expression increases 
during differentiation, and declines as cells become well differentiated (212). MHC-1 
mRNA level was very low (Fig 7B). Even though I checked 2 sets of primers, both gave 
me the same results. It is important to obtain another set of primers and check the result 
for the future studies.  
If the depletion of PDCD4 suppressed muscle cell differentiation, overexpression 
of the protein might rescue myotube formation. I conducted a transient overexpression 
experiment of PDCD4. Considering the quantification of western blot, the transfection 
efficiency was around 20% (Fig 8C, also see Supplemental figure 2A, B).  The PDCD4-
overexpressed-cells formed more myotube than control condition. This was seen both 
from morphological and western blot analyses (p<0.05) (Fig 8A, D).  A criticism of this 
study is the low transfection efficiency.  However, increasing the amount of a pro-
apoptotic protein as the name suggests, lead to cell death. However I did not measure 
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apoptosis. PDCD4 expression in Day 4 and 5 decreased (Fig 8B, C). This is because I 
used transient overexpression protocol in this study. If one uses stable overexpression 
protocol, one may obtain better results. 
PDCD4 is known as a tumor suppressor and an mRNA translation inhibitor. 
Overexpression of PDCD4 inhibits cancer cell progression. However this intervention 
has not reached human clinical trial yet. If we can overexpress PDCD4 in whole body, it 
acts as tumor suppressor to inhibit transcription factor regulatory proliferation of cancer 
cells. My data also show PDCD4 has an effect of maintaining skeletal muscle mass by 
inducing myotube formation. Therefore increased expression of PDCD4 may not only 
limit cancer cell growth, it also appears to hold potentials in promoting muscle cell 
recovery (Fig 9). 
Future Direction 
For overexpression experiment, I used a transient overexpression technique. A 
criticism of this study is the low transfection efficiency, which was approximately 30-
45% (Supplemental Figure 2C). Thus may be corrected (increased) by using stable 
overexpression protocol such as viral vectors. It is possible that increasing the amount of 
a pro-apoptotic protein may lead to cell death. Therefore, not only the efficiency of the 
transfection, but also the effect of increased expression on apoptosis needs to be 
examined. To examine the cell viability, I should use Trypan Blue ((Bio-Rad 
Laboratories ((Canada)) Ltd Life Science Group. Cat # 145-0021) to see the effect of 
transfection in apoptosis. Other way of overexpressing PDCD4, I can use mutant 
PDCD4. If I mutate Serine 67 of PDCD4, we can overexpress PDCD4. 
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Fig 9. Schematic of possible role of PDCD4 during myotube  
Once mTORC1 is activated, its downstream substrate S6K1 is phosphorylated. S6K1 can 
phosphorylate PDCD4. Phosphorylated PDCD4  (Ser 67) is targeted for ubiquitin-
mediated degradation by the ubiquitin protein ligase βTrCP (beta transducing repeat 
containing protein). If PDCD4 is in the unphosphorylated state, or overexpressed as done 
in this study, it may have an effect on myofibrillar protein expressions in myotube. It may 
affect the number of myotubes formed. It effects on myotube size needs to be studied. 
 
 
There was no significant difference in mRNA level of MHC-1 between treatments 
(control and PDCD4 knock-down cells). This may imply that protein level of MHC-1 
was disturbed by PDCD4 post-transcriptionally. It may be not only MHC-1, but the 
levels of other myotube formation markers may have been decreased their protein 
expressions by knock-down. Therefore, I should examine the mRNA and protein levels 
of myofibrillar proteins such as actin and MHC isoforms in control and PDCD4-depleted- 
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cells. I suspect that even though PDCD4 may have an effect on increasing the number of 
myotubes, but it may not necessarily increase muscle size, except myotube size is also 
affected. 
After examining in vitro, it is crucial to examine in vivo and confirm the results 
obtained in cell culture. For example, after causing muscle atrophy or injury with 
immobilization (tie up one leg) or muscle ablation with control and PDCD4-knockout-
mice, one can study the effect of PDCD4 inactivation on muscle regeneration. 
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FIGURES	                                                                     
 
Fig 1. 
  
 
Figure 1. PDCD4 expression in proliferating L6 cells (Day 0) and during 
differentiation (Day 1 to Day 6). PDCD4 expression was significantly increased from 
Day 0 to beginning of differentiation (Day 2) (p<0.05) after growth medium was changed 
to differentiation medium (A, B). MHC-1 was used as myotube formation indicator. 
Abundance of MHC-1 was observed starting Day 3, and significantly different starting 
Day 4 (p<0.05) (A, C).	  D0=day	  0,	  48	  hours	  after	   cells	  were	   seeded	   in	  6-­‐well	  plate.	  D1=1	  day	  after	  medium	  was	  changed	  to	  differentiation	  medium.	  Means ± SEM; n =3 
independent experiments; bars with different letters differ. 	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Fig 2.  
   
  
Figure 2. PDCD4 expression in proliferating C2C12 cells (Day 0) and during 
differentiation (Day 1 to Day 6). PDCD4 expression was significantly increased from 
Day 0 to beginning of differentiation (Day 1 and Day2) (p<0.05) after growth medium 
was changed to differentiation medium (A, B). MHC-1 was used as myotube formation 
indicator. Abundance of MHC-1 was observed starting Day 2 ad significantly different 
starting Day 3 (p<0.05) (A, C). D0=day	  0,	  48	  hours	  after	  cells	  were	  seeded	  in	  6-­‐well	  plate.	   D1=1	   day	   after	   medium	   was	   changed	   to	   differentiation	   medium.	   Means ± 
SEM; n=3 independent experiments; bars with different letters differ. 	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Fig 3. 
   	  	  	  
	  	  	  
Figure 3. Nuclear-Cytosolic expression of PDCD4 during L6 cell differentiation. 
Forty eight hours after cells were seeded, cells were harvested (D0) or shifted to 
differentiation medium (DM). After cells were scraped off the plates, the samples (whole 
lysate) were fractionated into cytosolic and nuclear fractions. Histone H2A was used as 
loading control for nuclear expression of PDCD4 and GAPDH for cytosolic one.  
Cytosolic expression at onset of differentiation was significantly different from myoblasts 
(p<0.05). N=nucleus	  C=cytosol,	  Means ± SEM; n=3 independent experiments; bars with 
different letters differ. 
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Fig 4. 
 
 
 
	  
Figure 4. Nuclear-Cytosolic expression of PDCD4 in C2C12 during cell 
differentiation. Forty eight hours after cells were seeded, cells were harvested (D0) or 
shift to differentiation medium (DM). After cells were scraped off the plates, the samples 
(whole lysate) were fractionated to cytosolic and nuclear fractions. Histone H2A was 
used as loading control for nuclear expression of PDCD4 and GAPDH for cytosolic one.  
Both cytosolic and nucleus expression at onset of differentiation were significantly 
different from myoblasts (p<0.05). N=nucleus	   C=cytosol,	   Means ± SEM; n=3 
independent experiments; bars with different letters differ. 
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Fig 5. 
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Figure 5. Rate of degradation of PDCD4 measurement by pulse chase assay. 
Experimental timeline of the pulse chase experiment (A). Cells were seeded at -48 hour 
point and 35S-methionine/cysteine was given to cells -24 hour point which is 24 hours 
after seeding cells. Zero hour is the point when cells were harvested following the 
“pulse” with 35S-methionine/cysteine. Image of the PDCD4-associated radioactivity of 
samples obtained by immunoprecipitation (IP) (B). Radioactive signals in IP samples 
were quantified at the end of “pulse” (0H) and at different times during the “chase” 
period (8H, 24H, 32H, 48H, 56H and 72H). Signals were expressed as a fraction of 0H 
values (C). Means ± SEM; n=3 independent experiments, bars with different letters differ 
(p< 0.05) IP 0H= sample of immunoprecipitation at 0 hour point. 
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Fig 6. 
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Figure 6. Effects of PDCD4 knockdown on L6 myoblast differentiation.	  PDCD4 was 
effectively knocked down (A, B). Cells treated with CTL or PDCD4 siRNA 
oligonucleotide were harvested and blotted for MHC-1 (A, C) and myogenin (A, D). 
Images of cells treated with CTL or PDCD4 siRNA oligonucleotide Day 0 and Day 4. 
Cell confluency was similar after 48 hours of siRNA treatment (D0 image, E). The 
western blot showed the myotube formation was impaired in PDCD4-depleted-cells 
(p<0.05). Means ± SEM; n=3 independent experiments, bars with different letters differ. 	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Fig 7.  
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Figure 7. mRNA expression of PDCD4 and myofibrillar proteins in control and 
PDCD4-depleted-cells. Cells were treated with control (CTL) or PDCD4 siRNA 
oligonucleotide (KD) in L6 cells and harvested D0 (48 hours after siRNA treatment) to 
D4. RNA was isolated from harvested cells and subjected to relative quantitative PCR 
(qPCR). mRNA data are expressed relative to mRNA level of house-keep gene (HPRT). 
PDCD4 mRNA levels on any day points except day 4 were significantly higher than in 
control cells (p<0.05) (A). MHC-1 mRNA levels were shown in (B). Myogenin mRNA 
levels on all day points were higher in control cells.  It was significantly higher in D2 and 
D3 (p<0.05) (C). Means ± SEM; n=2 independent experiments, * p<0.05, **<0.01, 
***<0.001, # p<0.05 and ##<0.01.  
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Fig 8. 
A.                    EGFP on Day 4                       EGFP- PDCD4 on Day 4  
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Figure 8. Effect of overexpression of PDCD4 on myotube formation. L6 cells were 
transfected with EGFP or EGFP- PDCD4 plasmid. Images were captured on Day 4, and 
the myotube formation was observed in both cells (A). Western blot images of control 
(EGFP) and overexpressed PDCD4 (PDCD4) are shown (B). PDCD4 expression (A, C) 
and MHC-1 (A, D) were quantified by using gamma tubulin as a loading control (P< 
0.05). Means ± SEM; * is p<0.05, **<0.01 and ****<0.0001. 
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APPENDIX	  	                                                                
Appendix A: Supplementary Figures 
 
 
  
Supplemental Figure 1:  βTrCP expression in proliferating L6 cells (Day 0) and 
during differentiation (Day 1 to Day 6). βTrCP expression was significantly increased 
from Day 0 to differentiation time (Day 1 to Day6) (p<0.05) after growth medium was 
changed to differentiation medium (A, B). D0=day	  0,	  48	  hours	  after	  cells	  were	  seeded	  in	   6-­‐well	   plate.	   D1=1	   day	   after	   medium	   was	   changed	   to	   differentiation	   medium.	  
Means  ± SEM; n = 2 independent experiments; bars with different letters differ. 
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Supplemental Figure 2:  EGFP image under florescent light. Images for cells 
transfected with EGFP were taken under florescent light with different magnification 48 
hours after transfection (A). Comparison with different sources of illumination (left panel 
with florescent light, right panel with white light) (B). The rate of overexpression was 
calculated (C).  
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Appendix C: Laboratory methods and protocols 
 
Splitting cells 
 
Cells	  
	   L6	  or	  C2C12	  muscle	  cells	  	  	  
Materials	  
• α- Modification of Eagle’s Medium (AMEM: Wisent Inc. Cat # 310-010-CL) for 
L6 cells, Dulbecco's Modified Eagle's Medium (DMEM: Wisent Inc. Cat # 319-
015-CL) for C2C12 cells 
• antibiotic/antimycotic (Ab-Am: Wisent Inc. Cat # 450-115-EL) 
• Fetal Bovine Serum (FBS; Cat # 12484-028) 
• Phosphate Buffered Saline (PBS; Wisent Inc. Cat # 311-010-CL) 
• Trypsin (Wisent Inc. Cat # 325-010043-EL ) 
• 10 cm culture dish (Cellstar. Cat # 82050-9160) 
• 20-200 ul pipette (BioShop Product ID:T010.10) 
• 100-1000 ul pipette (Diamed. Cat # Tec 520-1753) 
• 10 ml serological pipette (BD Falcon. CA 53300-523)  
• 5 ml serological pipette (BD Falcon. CA 53300-421) 
• Glass Pasteur Pipettes 
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Procedure 
1. After 48 hours of proliferation in growth medium (GM: for L6: AMEM 
supplemented with 10% FBS and 1% Ab-Am, for C2C12: DMEM supplemented 
with 10% FBS and 1% Ab-Am) in 10 cm culture dish, check the confluency of 
cells under the microscope. If it is 75-85% confluent, it is time to split cells. 
2. Put materials (ie. Trypsin, GM, PBS) in the water bath with 37°C .  
3. Turn on UV at least 15 minutes to sterile the fume hood.  
4. After sterilization, clean up the cell culture hood with 70% of ethanol. Before 
putting sterile equipment in the cell culture hood, materials have to be cleaned up 
with ethanol. Hose for waste liquid and your own hand with gloves as well. 
5. Take out the plates with proliferated cells from the incubator and put in the cell 
culture hood. 
6. Aspirate GM with vacuum attached with a glass Pasteur pipettes 
7. Wash the plate with 5 ml PBS to rinse off remaining GM. Use vacuum to remove 
PBS. 
8. Put 1 mL of Trypsin and move the plate gently to spread it everywhere in the 
plate.  
9. Place the plate in the incubator for 3 mins. 
10. While waiting for 3 mins, prepare new plate(s).  
---Put 10 ml of GM. 
---Write info (i.e. date, passage of the cells, type of the cell, your name) 
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11. Take out the plate from the incubator and tap the side of the plate to make sure the 
all cells are lifted from the bottom of the plate. 
12.  Check the plate under the microscope. If the cells are not moving, tap the plate 
and lift the cells from the bottom of the plate. 
13. Bring the plate back to the cell culture hood and add 5 ml of GM. 
14. Tile the plate and pipette up and down 5 times at one side of the plate. Those 
action allow lifted cell and GM mix together. 
15. Put the GM+cells into the new plate. The amount varies, (i.e. depends on the 
confluency before splitting) but it is about 800 µl-1 ml. 
16. Move the new plate(s) gently back and forth to mix well the cells and GM  
17. Put the new plate(s) in the incubator. 
18. Clean the cell culture hood with ethanol. 
19. Bring back materials in -20°C or 4°C fridge in the lab. 
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Harvesting Cells 
Cells	  
	   L6 or C2C12 muscle cells 	  	  
Materials	  
• Phosphate Buffered Saline (PBS; Wisent Inc. Cat # 311-010-CL) 
• 20-200 µl pipette (BioShop Product ID:T010.10) 
• 5 ml serological pipette (BD Falcon. Cat # CA 53300-421) or 10ml serological 
pipette (BD Falcon. Cat # CA 53300-523)  
• 1 ml (26Gx3/8) syringe (BD. Ref # 309625) 
• 1.5 ml eppendorf tube (Diamed. Tec 610-3167) 
• Cell scraper (BD Falcon. Ref # 353085) 
• Glass Pasteur Pipettes 
• lysis buffer 
Lysis Buffer 
 Tris Base (pH 7.5) 1M 25 mM 
10% SDS 2% 
0.5 M EDTA 1 mM 
phosphatase inhibitor 10 µl /ml 
protease inhibitor 10 µl /ml 
DTT 1 µl /ml 
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Lysis Buffer (total volume) 10 ml 15 ml 
Tris Base (pH 7.5) 1M     250 µl 375 µl 
10% SDS       2 ml 3 ml 
0.5 M EDTA      20 µl 30 µl 
phosphatase inhibitor     100 µl 150 µl 
protease inhibitor     100 µl 150 µl 
DTT      10 µl 15 µl 
DDH2O up tp 10 ml up to 15 ml 
 
 
Procedure 
1. Turn on UV at least 15 mins. 
2. Clean up in the cell culture hood with 70% of ethanol. Before putting sterile 
equipment in the cell culture hood, things have to be cleaned up with ethanol. 
Hose for waste liquid and your own hand with gloves as well. 
3. Take out the plate from the incubator. 
4. Aspirate differentiation medium (DM). 
5. Wash with 2 ml of PBS for each well to remove remaining DM in the 6-well 
plate. Gently swirl to make sure the remaining DM on the side of the well as well. 
Aspirate PBS. 
6. Put 75 µl of lysis buffer (depend of the experiment and the amount differ) and 
gently move the plate to spread out the buffer throughout the well. 
7. Use rubber policeman and scrub in the well. 
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8. Use syringe and take out all the cells and put in the eppendorph tube.  In the 
eppendorph tube, use syringe 3 times. 
9. After finishing collecting, take out the plate from the cell culture hood and put 
ethanol and put in the cell culture waste box. 
10.  Clean the cell culture hood with ethanol. 
11.  Close the cell culture hood, turn off the light. 
 
 
 
 
 
 
 
 
 
 
 
	   108	  
Cell Fractionation 
Cells	  
	   L6 or C2C12 muscle cells  
(Plates for Day 0 are in GM, proliferate in 48 hours, and  Day 1-6 are in DM, medium 
were changed every 48 hours. Days refer the time after DM was applied to cells.) 
 
 
Materials	  
• PBS (Wisent Inc. Cat # 311-010-CL) 
• Trypsin (Wisent Inc. Cat # 325-010043-EL ) 
• Cell scraper (BD Falcon. Ref # 353085) 
• 20-200 µl pipette (BioShop Product ID:T010.10) 
• 100-1000 µl (Diamed. Cat # Tec 520-1753) 
• 5 ml serological pipette (BD Falcon. Cat # CA 53300-421) 
• 10 ml serological pipette (BD Falcon. Cat # CA 53300-523)  
• 1.5 ml eppendorf tube (Diamed. Tec 610-3167) 
• Cell scraper (BD Falcon. Ref # 353085) 
• 15 ml polypropylene conical tube (BD Falcon Ref # 372096) 
• 50 ml polypropylene conical tube (BD Falcon Ref # 352070) 
• Buffer 1  
• Buffer 2 
• Microcentrifuges (placed in room temperature at 4℃) (Eppendorf. Centrifuge 
5415D) 
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• Eppendorf tube (Diamed. Tec 610-3167) 
• Digital Vortex Mixer (VWR Cat # 12620-854) 
• Glass Pasteur Pipettes 
Buffer 1 (50 ml) 
 Final concentration 
 10mM Tris Base (pH 7.4) 0.5 ml of 1M 
10mM NaCl 0.5 ml of 1M 
3 mM MgCl2 0.3 ml of 0.5M 
0.5% Np-40 0.25 ml 
DD H2O up to 50 mL 
protease inhibitor 10 µl /ml 
phosphatase inhibitor 10 µl /ml 
 
 
Buffer 2 (10 ml) 
 Final concentration 
 50 mM Tris Base (pH 7.4) 0.5 ml of 1M 
5 mM MgCl2 0.1 ml of 0.5 M 
0.1 mM EDTA 2 µl of 0.5 M 
1 mM DTT 10 µl of 1M 
40% Glycerol 4 ml 
DD H2O up to 10 mL 
protease inhibitor 10 µl /ml 
phosphatase inhibitor 10 µl /ml 
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Procedure 
1. Turn on UV at least 15 mins. 
2. Clean up in the cell culture hood with 70% of ethanol. Before putting sterile 
equipment in the cell culture hood, things have to be cleaned up with ethanol. 
Hose for waste liquid and your own hand with gloves as well. 
3. Take out the plate from the incubator. 
4. Aspirate GM (Day 0), DM (Day 1 through Day 6). 
5. Wash with 5 ml of PBS for each well to remove remaining GM or DM in the 10 
cm plate. Gently swirl to make sure the remaining GM or DM on the side of the 
well as well. Aspirate PBS. 
6. Put 1 mL of Trypsin and move the plate gently to spread it everywhere in the 
plate.  
7. Place the plate in the incubator for 3 mins. 
8. Put 5 ml of PBS in the plate and sack in and out and put in 15 ml polypropylene 
conical tube. 
9. Put another 2 ml of PBS in the plate and take out the reminding in the plate. 
10.  Centrifuge (2000 RPM) in 5 mins. 
11. Take out PBS and Trypsin (supernatant). 
12. Add 1 ml of PBS in the tube and bring back to the lab. 
13.  Place the tube on the ice on the lab bench, and use pipette (100-1000 µl) and 
resuspend cells. Every procedure is on the ice except when you are using 
microcentrifuge. 
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14. Put in the mixture of pellet and PBS in the 1.5 ml of eppendorf tube and 
centrifuge 2300 RPM for 3 minutes at 4°C in a microcentrifuge. 
15. Remove PBS.  Five hundred µl of Buffer 1 is added to the pellet and resuspended. 
16. The samples were put on ice and vortex for 15 sec every minute for 5 mins at low 
speed.  
17. From the resulting lysate, 100 µl aliquot was put in eppendorf tube.  
18. Centrifuge the eppendorf tube 2300 RPM for 3 minutes at 4 °C in a 
microcentrifuge. After centrifugation, the supernatant is collected as cytosol.  
19. To make sure there was no contamination, wash 2 times with 200 µl of Buffer 1.  
20. Resuspend the pellet with 150 µl of Buffer 2. This was the nuclear fraction.  
21. Place tube in -80°C. 
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35S-Methionine Pulse-Chase and Immunoprecipitation experiments 
 
Cells 
 L6 muscle cells  
 
Materials 
• Growth Medium (GM) with antibiotics: AMEM (Wisent Inc. Cat # 310-010-CL) 
supplemented with 10% FBS (Cat # 12484-028) and 1% Ab-Am (Wisent Inc. Cat 
# 450-115-EL) 
• Growth Medium (GM) without antibiotics: AMEM (Wisent Inc. Cat # 310-010-
CL) supplemented with 10% FBS (Cat # 12484-028) 
• Differentiation Medium (DM): (AMEM (Wisent Inc. Cat # 310-010-CL) 
supplemented with 2 % Horse Serum (HS: cat # 26050-088) and 1% Ab-Am 
(Wisent Inc. Cat # 450-115-EL)) 
• 35S-Methionine/Cystine (American Radiolabeled Chemicals, Inc) 
• Sterile L-Met/L-Cycteine 300 mM 
• PBS (Wisent Inc. Cat# 311-010-CL) 
• Microcentrifuges (placed in room temperature and 4°C) 
• 15 ml polypropylene conical tube (BD Falcon Ref # 372096) 
• 50 ml polypropylene conical tube (BD Falcon Ref  # 352070) 
• 5 ml serological pipette (BD Falcon. Cat # CA 53300-421) 
• 10 ml serological pipette (BD Falcon. Cat # CA 53300-523)  
• Eppendorf tube (Diamed. Tec 610-3167) 
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• Disposable Pasteur pipettes 5 3/4” (Fisher Scientific Cat # 12-678-6G) 
• Bench-coat 
• CHAPS buffer (see the recipe below) 
• CHAPS (solid) (sigma-Aldrich C5070) 
• High Salt buffer (HSB) (see the recipe below) 
• Low Salt Buffer (LSB) (see the recipe below) 
• Protein G (BioMag cat # 311812) 
• DynaMag™-2 Magnet (life technologies: cat # 12321D) 
 
 
CHAPS	  Buffer	  Recipe:	  
• CHAPS	  Buffer	  Recipe	  __	  500	  mL	  
Component	   Calculated	  Weight	   Measured	  Weight	  40mM	  HEPES	  [pH	  7.5]	   4.765	  g	   4.777	  g	  120mM	  NaCl	   3.507	  g	   3.509	  g	  1mM	  EDTA	   1mL	  of	  0.5M	  solution	   1	  mL	  of	  0.5M	  solution	  10mM	  Pyrophosphate	   1.110	  g	   1.107	  g	  10mM	  Glycerophosphate	   1.08	  g	   1.082	  g	  50	  mM	  NaF	   1.05	  g	   1.051	  g	  0.5mM	  Orthovandate	   1.25	  mL	  of	  200mM	  solution	   	  0.3	  %	  CHAPS	  added	  before	  use	  	  	  
• Store	  in	  4	  degree	  fridge	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• CHAPS	  Buffer	  with	  CHAPS	  	  
Component	   Proportion	  
CHAPS Buffer w/o CHAPS - 
CHAPS (solid) 0.30% 
1 mM DTT 1 µl/ml 
0.5 mM Nav 2.5 µl/ml 
1 mM Benz 5 µl/ml 
Protease Inhibitor 10 µl/ml 
Phosphatase Inhibitor 10 µl/ml 
6.25 mM NEM   
 
High	  Salt	  Buffer	  
	  50	  mM	  TrisHCl	   3.14 g 500	  mM	  NaCl	   11.68 g 5mM	  EDTA	   0.744 g 1%	  Triton	  X-­‐100	   4 ml 0.5%	  sodium	  deoxycholate	   2 g 
0.1%	  SDS	   0.4 g 0.04%	  β-­‐mercaptoethanol	   0.16 ml pH	  7.4	  at	  4°C	  
	  final	  volume	  is	  1liter	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Low	  Salt	  Buffer	  
	  20	  mM	  TrisHCl	   3.15 g 150	  mM	  NaCl	   8.76 g 5mM	  EDTA	   1.86 g 0.5	  %	  Triton	  X-­‐100	   5 ml 0.1	  %	  β-­‐mercaptoethanol	   1 ml pH	  7.4	  at	  4	  °C	  
	  final	  volume	  is	  1liter	  
	  
	  
 
	  
35S-Methionine/Cystine Pulse Period (24 hour after seeding cells in 21-10cm 
plates, cells are labelled with 35S-Methionine/Cystine.) 
1. Take out 35S-Methionine/Cystine in -80°C, 30 mins before conducting this 
protocol to thaw. 
2. Make medium with 4 mL of GM and 30 µCi per plate in 50 mL tubes.  
3. Take out plates from the incubator and aspire GM in the plates.  
4. Add GM+35S Methionine/Cystine  
5. Incubate 24 hours 
 
Chasing Period  
 Since I used radioactive material, I cannot vacuum medium in the wasting flask. 
Therefore, prepare radioactive wasting container in the cell culture hood, split bench-coat 
in the cell culture hood and turn on UV at least 15 minutes.  
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1. Make DM with extra methionine and cysteine (2 mM).   
2. Take out 18 plates from the incubator (3 of them are harvesting, so leave in the 
incubator in this point) 
3. Take out medium in the plate by using a gun pipette (instead of vacuuming) and 
put in the radioactive wasting container. Compared with vacuuming with glass 
Pasteur pipettes, we cannot aspirate medium well. Therefore, use 1000 µl pipette 
and remove the rest of the medium in the plates. 
4. Put 5 ml of PBS in the plates. Swirl and remove PBS with reminding medium 35S-
Methionine/Cysteine with the same manner as mentioned in step 2. Repeat twice. 
5. Add DM with 2 mM of methionine/cysteine in the plates. Since I change every 2 
hours at the beginning, add 2 ml of them. Before leaving the lab (longer hour 
incubating, add 5 ml). 
 
Harvesting and IP 
	  First day 
1. Prepare ice in the big container in radioactive area in the lab. 
2. Bring back 3 plates to the lab. 
3. Do the same things as step 3, 4 in the previous section: remove GM 35S-
Methionine/Cysteine with ice cold PBS twice. Put plates on ice. 
4. Put CHAPS buffer with CHAPS (450 µl/plate) and spread it with scraper gently. 
5. Wait 20 minutes. 
6. Put the lysate in the eppendorf tube (LOAD). 
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7. Prepare eppendorf tubes for IP with 400 µl	  of CHAPS buffer, 3 µl	  of PDCD4 
antibody, 300 µl	  of lysate. 
8. Bring IP tubes to the cold room. It is ideal to have rotating equipment, however 
we don’t have it, so I put on the tube rack and set those sample rotate as much as 
possible on the rocker for 20-24 hours.  
 
Second day (after 20-24 hours incubation) 
prepare Low Salt Buffer (LSB) with milk and High Salt Buffer (HSB).  They 
should be on ice. 
 
Low	  Salt	  Buffer	  with	  milk	  
	  Component	   Proportion	  Low	  salt	  Buffer	   -­‐	  1mM	  DTT	   1	  µL/mL	  0.5	  mM	  NaV	   2.5	  µL/mL	  1mM	  Benz	   5	  µL/mL	  Protease	  Inhibitor	   10	  µL/mL	  Phosphatase	  inhibitor	   10	  µL/mL	  6.25	  mM	  NEM	   	  	  milk	   0.10%	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High	  Salt	  Buffer	  
	  Component	   Proportion	  High	  salt	  Buffer	   -­‐	  1mM	  DTT	   	  	  1µL/mL	  0.5	  mM	  NaV	   2.5	  µL/mL	  1mM	  Benz	   5	  µL/mL	  Protease	  Inhibitor	   10	  µL/mL	  Phosphatase	  Inhibitor	   10	  µL/mL	  6.25	  mM	  NEM	   	  	  
 
1. The next day (20-24 hours later), prepare magnetic beads.  
 
• Pick up magnetic beads from 4°C fridge. Before taking out magnetic 
beads, put the bottle up and down to make pullets are resuspended. 
• Prepare 1.5 ml eppendorf tube and set on the magnetic rack. 
• Put 300 µl (100 µl/sample) of resuspended magnetic beads in an eppendorf 
tube (enough for 3 samples). 
• Wait 1-2 minutes. 
• Take out the supernatant. 
• Take out the tube from the magnetic rack and put 500 µl LSB without 
additive (original bottle in the fridge), resuspend by hand (not by pipette). 
Gently shake the eppendorf tube up and down.  
• Put the eppendorf tube back on the magnetic rack and wait 1.5 minutes 
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• Take out supernatant (pipette tip should touch the other side of the tube. 
Never touch the magnetic beads).  
• Repeat those washing process 3 times. 
• Put 320 µl	  of LSB with milk (recipe is p.117) (since we need at least 100 
µl/sample, make sure I have enough). 
• Resuspend the eppendorf tube with moving gently up and down. 
2. Add 100 µl of magnetic beads to each sample and incubate samples in the cold 
room 1-2 hours (the same as the first day step 8, rotating on the rocker. To be sure 
about the sample rotation, check the sample every 20 minutes) 
3. Bring back samples to the lab and put on the magnetic rack. 
4. Take out supernatant and put on ice. 
5. Put 500 µl	  of LSB with milk/tube and resuspend. 
6. Wait 1 minute and invert the rack (because magnetic beads may remain on the 
cap). Wait another 30 seconds. 
7. Take out supernatant (2 times washing). 
8. Put 1 mL of HSB and resuspend. 
9. Wait 1 minute and invert the rack and wait another 30 seconds. 
10. Take out supernatant. 
11. Take out samples from the magnetic rack and put 100 µl	  of 1X SB (we usually 
store 4X SB in the lab, therefore dilute with double distilled water). Try to shoot 
the magnetic beads with 1X SB and let the beads come down to the bottom of the 
tubes. 
12. Vortex with gentle speed (3-4). 
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13. Boil samples for 5 minutes at 95°C. 
14. Vortex for 3-5 seconds. 
15. Centrifuge for 2 minutes at 13,000 g force. 
16. Place samples on the magnetic rack and wait 2 minutes. 
17. Transfer supernatant to new eppendof tubes (Eluate). 
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RNAi 
Materials 
• Opti-MEM (Life technologies: cat # 31985-070) 
• Lipofectamine RNAiMAX reagent (Life technologies: cat # 13778-150) 
• siRNA scramble or PDCD4 #1 or #2 (Sigma Aldrich) 
• 15 ml polypropylene conical tubes (BD Falcon Ref # 372096) 
• Growth Medium (GM) without antibiotics (AMEM (Wisent Inc. Cat # 310-010-
CL) supplemented with 10% FBS (Cat # 12484-028) ) 
• Growth Medium (GM) (AMEM (Wisent Inc. Cat # 310-010-CL) supplemented 
with 10% FBS (Wisent Inc. Cat # 12484-028) and 1% Ab-Am (Wisent Inc. Cat # 
450-115-EL)) 
• 6 well plates (Cellstar: cat # 657160) 
	  
component	   amount	   Website	  
	  
cells	   250000/well	   250000/well	  
A	  
Opti-­‐MEM	  Medium	   118	  µl/well	   150	  µl/well	  
Lipofectamine	  RNAiMAX	  reagent	   7.07	  µl/well	   9	  µl/well	  
B	  
Opti-­‐MEM	  Medium	   121.4	  µl/wel	   150	  µl/well	  
siRNA	  (10µΜ)	   3.54	  µl/well	   9	  µl/well	  
 
*”amount” is the one I modified from the website one. Since I need to add 250 µl/well, 
the “Website” one is a lot of wasting.  Most important thing is to have 30nM of RNAi.  
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This info is older version in Life Technologies, therefore, please check the current one on 
the website. 
1. In the cell culture hood, prepare 4 of 15 ml tubes and label as Optimum, 
Lipofectamine (for making “A”) PDCD4 (for making part of “B-1”) and 
Scramble (for making part of “B-2”). 
2. Pour Optimum from the bottle to the 15 ml-Optimum tube (Not to touch the 
mouth of the bottle, not to use pipette gun). 
3. Make A in Lipofectamine tube.  
4. Make B-1 and B-2 in the PDCD4 and Scramble tubes. 
5. Put A into B-1 and B-2 and gently move the tube and mix well. 
6. Wait at least 5 minutes. 
7. While waiting, add 1 mL/well of GM without antibiotics, and add cells/well. 
8. Add 250 µl/well of diluted lipofectamine RNAiMAX Reagent 
9. Next day, add 1 mL/well of GM (with antibiotics). 
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mRNA	  Experiment	  
RNAi	  treatment	  
Cells	  	  
• 250000 cells/well and 2 wells of sample put in one tube 
• 2 samples/day/treatment (scramble as control or PDCD4 knock-down) 
Protocol 
Refer the mRNA section 
 
RNA	  extraction	  
Materials	  	  
TRIzol Plus RNA Purification Kit (Life technologies Cat # 12183555) 
 
Check the website and obtain the manual of TRIzol Plus RNA Purification Kit. 
Follow the protocol. 
 
RNA concentration determination 
Materials	  	  
• Smart SpecTM Plus (Bio-Rad Laboratories ((Canada)) Ltd Life Science Group) 
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• TrUView disposable Cuvette (Bio-Rad Laboratories ((Canada)) Ltd Life Science 
Group. Cat # 170-2510) 
• Buffer EB (QIAGEN. cat # 19086) 
 
How to use Smart SpecTM Plus (Bio-Rad Laboratories ((Canada)) Ltd Life Science 
Group) 
• Flick the power button behind Smart SpecTM Plus. 
• Smart SpecTM Plus start beeping and start blinking. 
• Press “DNA RNA” button. 
• Choose Nucleic RNA and the setting should be 1.0 = 40 µg/ml 
• Put 297 µl of EB buffer in Cuvette and press “Read Blank” 
• Take out Cuvette from Smart SpecTM Plus and discard the content and put 297 µl 
of EB buffer and 3 µl of RNA and press Read Sample”. Write down absorbance 
of 260, RNA concentration. Press A260:A280 and record the ratio. 
 
 
How to obtain cDNA 
Materials 
• iScriptTM Advanced cDNA Synthesis Kit for RT-qPCR (Bio-Rad Laboratories 
((Canada)) Ltd Life Science Group, cat#1725038) 
• Autoclaved 1.5 ml eppendorf tubes 
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• PCR 8-cap strips (Bio-Rad Laboratories ((Canada)) Ltd Life Science Group, 
cat # TCS 0803) 
• PCR tubes (Bio-Rad Laboratories ((Canada)) Ltd Life Science Group, cat # 
TLS 0851) 
• 5345 PCR Mastercycker, Gradient Thermal Cycler (eppendorf) 
    Protecol 
Follow the company’s protocol. Except the “Reaction Protocol” For reverse 
transcription, I did 60 minutes instead of 30 minutes at 42°C. 
 
qPCR 
     Materials 
• SsoAdvancedTM Universal SYBR Green Supermix (Bio-Rad Laboratories 
((Canada)) Ltd Life Science Group, cat#172-5271) 
• cDNA (obtained previous section) 
• Primers (forward) 
• Primers (reverse) 
• Autoclaved double distilled water 
• PCR 8-cap strips (Bio-Rad Laboratories ((Canada)) Ltd Life Science Group, 
cat # TCS 0803) 
• PCR tubes (Bio-Rad Laboratories ((Canada)) Ltd Life Science Group, cat # 
TLS 0851) 
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• VWR Galaxy mini 
 
     Protocol 
• Mix the following compoents. cDNA add the last. 
 
Component	  
	  SsoAdvance	   10	  µl/tube	  
Primer	  (F)	   1.25	  µl/tube	  
Primer	  (R)	   1.25	  µl/tube	  
DD	  water	   6	  µl/tube	  
Diluted	  cDNA	   1.5	  µl/tube	  
 
• Centrifuge 2 seconds. 
qPCR cycle 
1. 95 °C: 2 mins 
2. 95 °C: 10 sec 
3. 57 °C: 20 sec 
4. Plate read 
5. Go to 2, 40 times 
6. 95 °C: 10 sec 
7. 65 °C: 31 sec 
8. 65 °C: 5 sec 
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9. Plate read 
10. Go to 8, 60 times 
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Overexpression Experiment 
Cells	  
	   L6 muscle cells (160000 cells/well) 
 
Materials	  
• Lipofectamin 2000	  (Life technologies: cat # 11668-019) 
• Opti-MEM (Life technologies: cat # 31985-070) 
• 6-­‐well	  plates	  (Cellstar: cat # 657160)	  
• 2.5	  µg plasmid DNAs	  
• Autoclaved Eppendorf tube (Diamed. Tec 610-3167) or  (if the amount of total 
mixture is more than 1.5 ml, use 15 ml polypropylene conical tube (BD Falcon 
Ref # 372096) 
 
Procedure 
• Seed cells to be 70-75% confluency in 24 hours.	  
	  24	  hours	  later:	  
• Turn	  on	  UV	  at	  least	  15	  mins	  
• Clean	  up	  in	  the	  cell	  culture	  hood	  with	  70%	  of	  ethanol.	  Before	  putting	  sterile	  equipment	  in	  the	  cell	  culture	  hood,	  things	  have	  to	  be	  cleaned	  up	  with	  ethanol.	  Hose	  for	  waste	  liquid	  and	  your	  own	  hand	  with	  gloves	  as	  well.	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• Keep	  OPTIMEM,	  Lipofectamine	  2000	  and	  DNA	  on	  ice.	  
• Make	  mixture	  of	  A	  	  
	  
mixture	  A	   per	  well	  
OPTIMEM	   125	  ul	  
Lipofectamine	  2000	   5	  ul	  
	  
• Make	  mixture	  of	  B	  
mixture	  B	   per	  well	  
OPTIMEM	   125	  ul	  
DNA	   2.5	  ug	  
	  
• Put mixture A into mixture B. The amount has to be equal amount. Since the 
amount of mixture B depends on the DNA, calculate and make sure the total 
amount of mixture A is more than total amount of mixture B (considering the 
pipetting error). 
• Wait at least 5 minutes. 
• While waiting, wash plates with AMEM (without any supplementation) 
• Add	  1	  mL	  AMEM (without any supplementation) per well. 
• Add 250	  µl	  of DNA lipid complex per well. 
• After 2-3 hours later, add 10% of FBS (since 1,25mL of AMEM+DNA lipid 
complex are in a well, add 125 µl of FBS should be added per well). 	  
